

Inventor Search

Ward 10/621,983


14/05/2005

=> d ibib abs hitstr 123 1-17

L23 ANSWER 1 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:546489 HCPLUS
 DOCUMENT NUMBER: 141:106474
 TITLE: Preparation of MEK inhibiting oxa- and thiadiazol-2-ylphenylamines
 INVENTOR(S): Biwersi, Cathlin Marie; Warmus, Joseph Scott; Zhang, Lu Yan; Barrett, Stephen Douglas; Kaufman, Michael David; Plummer, Mark Stephen; Reed, Jessica Elizabeth
 PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
 SOURCE: PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056789	A1	20040708	WO 2003-IB5787	20031208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005004186	A1	20050106	US 2003-725206	20031201
PRIORITY APPLN. INFO.:			US 2002-435155P	P 20021220
			US 2003-509701P	P 20031008

OTHER SOURCE(S): MARPAT 141:106474
 GI



AB Title compds. I [X = Nh, O, S; R1 = (un)substituted alkyl, alkenyl, C.tplbond.CH, alkoxy, acyl, CONH2, CO2H, alkylthio; R2 = F, CH2F, CHF2, CF3; R3 = (un)substituted alkyl, alkenyl, aryl, OH, SH; R4 = H, halogen; R5 = H, F] were prepared for use as inhibitors of MAPKIERK Kinase (MEK) enzymes in immunomodulation and in the treatment and


alleviation of inflammation, and proliferative diseases such as cancer and restenosis (no data). Thus, 2-(4-bromo-2-fluorophenylamino)-3,4-difluorobenzoic acid was converted to its hydrazide and cyclized with BrCN to give I [X = O, R1 = Br, R2, R5 = F, R3 = NH2, R4 = H].

IT 534-03-2, 2-Amino-1,3-propanediol 61278-21-5,
(S)-(-)-3-Amino-1,2-propanediol 66211-46-9, (2R)-3-Amino-1,2-propanediol

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of MEK inhibiting oxa- and thiadiazol-2-ylphenylamines)

RN 534-03-2 HCPLUS


CN 1,3-Propanediol, 2-amino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 61278-21-5 HCPLUS

CN 1,2-Propanediol, 3-amino-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 66211-46-9 HCPLUS

CN 1,2-Propanediol, 3-amino-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:80385 HCPLUS

DOCUMENT NUMBER: 140:146153

TITLE: Preparation of pyrimidopyrimidinones as kinase inhibitors

INVENTOR(S): Chivikas, Connolly Cleo J.; Deur, Christopher James; Hamby, James Marino; Hoyer, Denton Wade; Limberakis, Chris; Reed, Jessica Elizabeth; Schroeder, Mel Conrad; Taylor, Clarke

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 44 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004019210	A1	20040129	US 2003-621983	20030717
CA 2493633	AA	20040205	CA 2003-2493633	20030721
WO 2004011465	A1	20040205	WO 2003-IB3359	20030721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-398638P	P 20020725
			WO 2003-IB3359	W 20030721

OTHER SOURCE(S): MARPAT 140:146153

GI



AB This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimidopyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula I [A = O, NH₂, mono(or di)alkylamino, NHCONHR₁₂ (wherein R₁₂ = alkyl, alklenecycloalkyl); B, C, D = CH, N (with the proviso that C and D are not both N); R₁ = alkyl]

(optionally substituted by CO₂H), (un)substituted Ph, CH₂Ph, piperidinyl, etc.; R₂ = H, Cl, F; R₃ = H, Cl, F (at least one of R₂ or R₃ = F); R₄ = H, OH, OMe, OEt (if R₄ = H, R₂ and R₃ is not H); R₅ = OMe, OEt; R₆ = H, alkyl-NH₂, O-alkyl-NH₂, etc.] that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediates for their synthesis, as well as pharmaceutical compns. and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer (no biol. data given). Synthesis of 35 title compds. I is described. E.g., a multi-step synthesis of II was given.

IT 62031-54-3, Fibroblast growth factor 62229-50-9,
Epidermal growth factor 141349-86-2, Cdk2 kinase
143375-65-9, Cdc2 kinase 144697-17-6, c-Src
kinase 147014-97-9, Cdk4 kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrimidopyrimidinones as kinase inhibitors
)

RN 62031-54-3 HCPLUS
CN Fibroblast growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 62229-50-9 HCPLUS
CN Epidermal growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 141349-86-2 HCPLUS
CN Kinase (phosphorylating), gene cdk2 protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 143375-65-9 HCPLUS
CN Kinase (phosphorylating), gene cdc2 protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 144697-17-6 HCPLUS
CN Kinase (phosphorylating), gene c-src protein (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 147014-97-9 HCPLUS
CN Kinase (phosphorylating), protein p33CDK4 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 651734-15-5P 651734-16-6P 651734-35-9P
651734-43-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidopyrimidinones as kinase inhibitors
)


RN 651734-15-5 HCPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-16-6 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[[(4S,5S)-5-(hydroxymethyl)-2-phenyl-1,3-dioxolan-4-yl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-35-9 HCPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 651734-43-9 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


IT 651734-14-4P 651734-17-7P 651734-18-8P
651734-19-9P 651734-20-2P 651734-21-3P
651734-22-4P 651734-23-5P 651734-24-6P
651734-25-7P 651734-26-8P 651734-27-9P
651734-28-0P 651734-29-1P 651734-30-4P
651734-31-5P 651734-32-6P 651734-33-7P
651734-34-8P 651734-36-0P 651734-38-2P
651734-39-3P 651734-40-6P 651734-41-7P
651734-42-8P 651734-45-1P 651734-46-2P
651734-47-3P 651734-48-4P 651734-49-5P
651734-50-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidinones as kinase inhibitors
)

RN 651734-14-4 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-17-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[(2S,3S)-2,3,4-trihydroxybutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-18-8 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 651734-19-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)ethyl)amino]- (9CI) (CA INDEX NAME)



RN 651734-20-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2-hydroxypropyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-21-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-(2-hydroxyethoxy)ethyl)amino]- (9CI)

(CA INDEX NAME)




RN 651734-22-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopropyl-7-[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-23-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[4-(diethylamino)butyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-24-6 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[2-hydroxy-1-(hydroxymethyl)ethyl]amino- (9CI) (CA INDEX NAME)



RN 651734-25-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 651734-26-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R,3R)-2,3-dihydroxybutyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-27-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R)-2,3-dihydroxypropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-28-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-amino-2,3-dihydroxybutyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-29-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2S,3S)-2,3,4-trihydroxybutyl]amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-30-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 651734-31-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2S,3S)-4-amino-2,3-dihydroxybutyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-32-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-[bis(2-


hydroxyethyl)amino]propyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-33-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2S)-2,3-dihydroxypropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651734-34-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R,3R)-2,3-dihydroxybutyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-36-0 HCPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
(CA INDEX NAME)


RN 651734-38-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-1-(4-piperidinyl)-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)


CM 1

CRN 651734-37-1


CMF C19 H22 F2 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 651734-39-3 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 651734-40-6 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(4-hydroxybutyl)amino]- (9CI) (CA INDEX NAME)



RN 651734-41-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(2S)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 651734-42-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 651734-45-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-1-(4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 651734-44-0


CMF C20 H24 F2 N6 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 651734-46-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R)-2,3-dihydroxypropyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-47-3 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[[4-(diethylamino)butyl]amino]-3-(3-ethoxy-2,6-difluorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-48-4 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[[(2R)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-49-5 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 651734-50-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



IT 75-65-0, t-Butanol, reactions 100-46-9, Benzylamine, reactions 367-27-1, 2,4-Difluorophenol 534-03-2, Serinol 616-29-5, 1,3-Diamino-2-hydroxypropane 765-30-0, Cyclopropylamine 770-31-0 929-06-6, 2-(2-Aminoethoxy)ethanol 2150-37-0, Methyl 3,5-dimethoxy benzoate 4985-85-7, N-(3-Aminopropyl)diethanolamine 5909-24-0, 4-Chloro-2-methylsulfonylpyrimidine-5-carboxylic acid ethyl ester 13325-10-5, 4-Aminobutan-1-ol 17159-80-7, Ethyl-4-hydroxycyclohexanecarboxylate 27431-62-5, 4-Diethylaminobutylamine 27489-62-9, trans-4-Aminocyclohexanol 32798-38-2, 1,4-Diaminobutane-2,3-diol 36629-42-2, Methyl pentafluorobenzoate 61278-21-5 66211-46-9 104769-25-7, (2S,3S)-1,4-Diaminobutane-2,3-diol 109384-19-2, tert-Butyl-4-hydroxy-1-piperidinecarboxylate 155322-89-7, (4S,5R)-2,2,5-Trimethyl[1,3]dioxolane-4-carbonyl chloride 168113-19-7 185040-35-1 211245-64-6 651734-99-5, 1-Cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-methylsulfinyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 651735-01-2 651735-16-9 651735-17-0 651735-19-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidopyrimidinones as kinase inhibitors)


RN 75-65-0 HCAPLUS
 CN 2-Propanol, 2-methyl- (9CI) (CA INDEX NAME)




RN 100-46-9 HCAPLUS
 CN Benzenemethanamine (9CI) (CA INDEX NAME)




RN 367-27-1 HCAPLUS
 CN Phenol, 2,4-difluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 534-03-2 HCAPLUS
 CN 1,3-Propanediol, 2-amino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 616-29-5 HCAPLUS
 CN 2-Propanol, 1,3-diamino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 765-30-0 HCAPLUS
 CN Cyclopropanamine (9CI) (CA INDEX NAME)




RN 770-31-0 HCAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-(methylthio)- (6CI, 7CI, 8CI, 9CI)
 (CA INDEX NAME)




RN 929-06-6 HCAPLUS
 CN Ethanol, 2-(2-aminoethoxy)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 2150-37-0 HCAPLUS
 CN Benzoic acid, 3,5-dimethoxy-, methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 4985-85-7 HCAPLUS
 CN Ethanol, 2,2'-(3-aminopropyl)imino]bis- (9CI) (CA INDEX NAME)




RN 5909-24-0 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 13325-10-5 HCAPLUS
 CN 1-Butanol, 4-amino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$\text{H}_2\text{N}-\text{(CH}_2)_4-\text{OH}$

RN 17159-80-7 HCPLUS
 CN Cyclohexanecarboxylic acid, 4-hydroxy-, ethyl ester (6CI, 7CI, 8CI, 9CI)
 (CA INDEX NAME)




RN 27431-62-5 HCPLUS
 CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)


$\text{H}_2\text{N}-\text{(CH}_2)_4-\text{NET}_2$

RN 27489-62-9 HCPLUS
 CN Cyclohexanol, 4-amino-, trans- (8CI, 9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 32798-38-2 HCPLUS
 CN 2,3-Butanediol, 1,4-diamino- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 36629-42-2 HCPLUS
 CN Benzoic acid, pentafluoro-, methyl ester (9CI) (CA INDEX NAME)



RN 61278-21-5 HCPLUS

CN 1,2-Propanediol, 3-amino-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 66211-46-9 HCPLUS

CN 1,2-Propanediol, 3-amino-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 104769-25-7 HCPLUS


CN 2,3-Butanediol, 1,4-diamino-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109384-19-2 HCPLUS


CN 1-Piperidinecarboxylic acid, 4-hydroxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 155322-89-7 HCPLUS

CN 1,3-Dioxolane-4-carbonyl chloride, 2,2,5-trimethyl-, (4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168113-19-7 HCAPLUS


CN 1,2,3-Butanetriol, 4-amino-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185040-35-1 HCAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-(ethylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 211245-64-6 HCAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopentylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 651734-99-5 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 651735-01-2 HCPLUS


CN 1,3-Dioxolane-4-methanol, 5-(aminomethyl)-2-phenyl-, (4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651735-16-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylsulfinyl)- (9CI) (CA INDEX NAME)




RN 651735-17-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 651735-19-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(3-ethoxy-2,6-difluorophenyl)-3,4-dihydro-7-(methylsulfinyl)- (9CI) (CA INDEX NAME)




IT 348-20-9P, 1-Ethoxy-2,4-difluorobenzene 122590-82-3P,
 Methyl 4-(benzylamino)-2,3,5,6-tetrafluorobenzoate 211247-46-0P
 651734-51-9P, Methyl 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoate 651734-52-0P, 4-(Benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic Acid 651734-53-1P, N-Benzyl-2,6-difluoro-3,5-dimethoxyaniline 651734-54-2P, 2,6-Difluoro-3,5-dimethoxyaniline 651734-55-3P, 2,6-Difluoro-3,5-dimethoxybenzoic acid Methyl Ester 651734-56-4P, 2,6-Difluoro-3,5-dimethoxybenzoic acid 651734-57-5P, (2,6-Difluoro-3,5-dimethoxyphenyl)carbamic acid tert-Butyl Ester 651734-58-6P, 2-Fluoro-3,5-dimethoxybenzoic Acid Methyl Ester 651734-59-7P, 2-Fluoro-3,5-dimethoxybenzoic acid 651734-60-0P, (2-Fluoro-3,5-dimethoxyphenyl)carbamic Acid tert-Butyl Ester 651734-61-1P, 2-Fluoro-3,5-dimethoxyphenylamine 651734-62-2P, 3-Ethoxy-2,6-difluorobenzoic Acid 651734-63-3P, (3-Ethoxy-2,6-difluorophenyl)carbamic Acid tert-Butyl Ester 651734-64-4P, 3-Ethoxy-2,6-difluorophenylamine 651734-65-5P, 4-Cyclopropylamino-2-methylsulfanylpyrimidine-5-Carboxylic Acid Ethyl Ester 651734-66-6P 651734-67-7P
 651734-68-8P 651734-69-9P 651734-70-2P
 651734-71-3P 651734-72-4P 651734-73-5P
 651734-74-6P 651734-75-7P 651734-76-8P,
 1-Cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-methylsulfanyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 651734-77-9P,
 1-Cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-methylsulfanyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 651734-79-1P
 651734-81-5P 651734-83-7P 651734-86-0P
 651734-88-2P, (4S,5R)-2,2,5-Trimethyl-[1,3]dioxolane-4-carboxylic Acid Benzylamide 651734-90-6P, (2S,3R)-N-Benzyl-2,3-

dihydroxybutyramide 651734-92-8P, (2R,3R)-1-Benzylaminobutane-2,3-diol 651734-94-0P, (2R,3R)-1-Aminobutane-2,3-diol
651735-06-7P 651735-08-9P 651735-10-3P,
 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-7-methylsulfanyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 651735-13-6P 651735-14-7P
651735-15-8P 651735-18-1P 651735-20-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrimidopyrimidinones as kinase inhibitors)


RN 348-20-9 HCPLUS
 CN Benzene, 1-ethoxy-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 122590-82-3 HCPLUS
 CN Benzoic acid, 2,3,5,6-tetrafluoro-4-[(phenylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 211247-46-0 HCPLUS
 CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopropylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-51-9 HCPLUS
 CN Benzoic acid, 3,5-difluoro-2,6-dimethoxy-4-[(phenylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 651734-52-0 HCPLUS

CN Benzoic acid, 3,5-difluoro-2,6-dimethoxy-4-[(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 651734-53-1 HCPLUS

CN Benzenemethanamine, N-(2,6-difluoro-3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 651734-54-2 HCPLUS

CN Benzenamine, 2,6-difluoro-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 651734-55-3 HCPLUS


CN Benzoic acid, 2,6-difluoro-3,5-dimethoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 651734-56-4 HCAPLUS
 CN Benzoic acid, 2,6-difluoro-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 651734-57-5 HCAPLUS
 CN Carbamic acid, (2,6-difluoro-3,5-dimethoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651734-58-6 HCAPLUS
 CN Benzoic acid, 2-fluoro-3,5-dimethoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 651734-59-7 HCAPLUS
 CN Benzoic acid, 2-fluoro-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 651734-60-0 HCAPLUS

CN Carbamic acid, (2-fluoro-3,5-dimethoxyphenyl)-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 651734-61-1 HCAPLUS

CN Benzenamine, 2-fluoro-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 651734-62-2 HCAPLUS

CN Benzoic acid, 3-ethoxy-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 651734-63-3 HCAPLUS


CN Carbamic acid, (3-ethoxy-2,6-difluorophenyl)-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 651734-64-4 HCAPLUS
 CN Benzenamine, 3-ethoxy-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 651734-65-5 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(cyclopropylamino)-2-(methylthio)-, ethyl ester (9CI) (CA INDEX NAME)



RN 651734-66-6 HCAPLUS
 CN 5-Pyrimidinemethanol, 4-(cyclopropylamino)-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 651734-67-7 HCAPLUS
 CN 4-Pyrimidinamine, 5-[(2,6-difluoro-3,5-dimethoxyphenyl)imino]methyl-N-ethyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-68-8 HCPLUS

CN 4-Pyrimidinamine, N-(cyclopropyl)-5-[(2,6-difluoro-3,5-dimethoxyphenyl)imino]methyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-69-9 HCPLUS

CN 4-Pyrimidinamine, N-(cyclopentyl)-5-[(2,6-difluoro-3,5-dimethoxyphenyl)imino]methyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-70-2 HCPLUS

CN 4-Pyrimidinamine, N-(cyclopentyl)-5-[(3-ethoxy-2,6-difluorophenyl)imino]methyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-71-3 HCPLUS

CN 5-Pyrimidinemethanamine, N-(2,6-difluoro-3,5-dimethoxyphenyl)-4-(ethylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-72-4 HCPLUS

CN 5-Pyrimidinemethanamine, 4-(cyclopropylamino)-N-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-73-5 HCPLUS

CN 5-Pyrimidinemethanamine, 4-(cyclopentylamino)-N-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-74-6 HCPLUS

CN 5-Pyrimidinemethanamine, 4-(cyclopentylamino)-N-(3-ethoxy-2,6-difluorophenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-75-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-76-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-77-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-79-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(3-ethoxy-2,6-difluorophenyl)-3,4-dihydro-7-(methylthio)- (9CI) (CA INDEX NAME)




RN 651734-81-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(methylsulfinyl)- (9CI) (CA INDEX NAME)




RN 651734-83-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 651734-86-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-ethoxy-2,6-difluorophenyl)-1-(1-ethylpropyl)-3,4-dihydro-7-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 651734-88-2 HCAPLUS

CN 1,3-Dioxolane-4-carboxamide, 2,2,5-trimethyl-N-(phenylmethyl)-, (4S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-90-6 HCAPLUS

CN Butanamide, 2,3-dihydroxy-N-(phenylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-92-8 HCAPLUS

CN 2,3-Butanediol, 1-[(phenylmethyl)amino]-, (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-94-0 HCAPLUS


CN 2,3-Butanediol, 1-amino-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651735-06-7 HCPLUS

CN 5-Pyrimidinemethanamine, 4-amino-N-(2,6-difluoro-3,5-dimethoxyphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651735-08-9 HCPLUS

CN 4-Pyrimidinamine, 5-[(2,6-difluoro-3,5-dimethoxyphenyl)imino]methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 651735-10-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylthio)- (9CI) (CA INDEX NAME)




RN 651735-13-6 HCPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylthio)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 651735-14-7 HCPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylsulfinyl)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 651735-15-8 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylsulfinyl)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 651735-18-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[7-amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651735-20-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(methylthio)-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L23 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:123003 HCAPLUS
 DOCUMENT NUMBER: 136:183833
 TITLE: Preparation of 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones as novel antiangiogenic agents useful for the treatment of diseases associated with aberrant blood vessel proliferation.
 INVENTOR(S): Hamby, James Marino; Klutchko, Sylvester;
 Kramer, James Bernard
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012238	A2	20020214	WO 2001-US22881	20010720
WO 2002012238	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417942	AA	20020214	CA 2001-2417942	20010720
AU 2001077032	A5	20020218	AU 2001-77032	20010720
EP 1307450	A2	20030507	EP 2001-954811	20010720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004519422	T2	20040702	JP 2002-518213	20010720
BR 2001012857	A	20050209	BR 2001-12857	20010720
US 2003220345	A1	20031127	US 2003-343847	20030204
PRIORITY APPLN. INFO.:			US 2000-223083P	P 20000804

OTHER SOURCE(S) : MARPAT 136:183833
GI

WO 2001-US22881 W 20010720

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The invention discloses the preparation and the use of title compds. I, wherein: R₁, R₂, R₅, R₆ = H, halogen, alkyl, alkoxy, thio, thioalkyl, hydroxy, alkanoyl, nitrile, nitro, alkanoyloxy, CF₃, alkyl ester, NH₂ or derivs., aminoalkoxy, etc.; R₃, R₄ = alkyl, or haloalkyl; R₇ = H, alkyl, alkenyl, alkynyl, or cycloalkyl; including their pharmaceutically acceptable salts and compns. as antiangiogenic agents. Compds. I, are useful for treating diseases, resulting from uncontrolled cellular proliferation such as cancer, atherosclerosis, rheumatoid arthritis, and psoriasis. The invention compds. exhibited greater selectivity for **inhibiting VEGF and FGF, without inhibiting the Src family c-Src and Lck kinases.** Claims include 12 specific compds. and the syntheses of 5 especially preferred compds. are described. For example, condensation of 3,5-dimethoxyphenylacetonitrile with aldehyde II, followed by acylation of the resultant imine, hydrolysis, oxidation, and sulfoxide displacement with the lithium salt of 4-amino-2,6-dimethoxypyridine, provided the most preferred compound III in 5 steps. Tyrosine kinase inhibition data (IC₅₀ = μM) was disclosed for compound I (R₁, R₅, R₆ = H; R₂ = 3-Cl; R₃, R₄ = Me; and R₇ = Et) against: FGFr = 0.0002, VEGF-2 = 0.003, PDGF = 5, Lck = 2.77, and c-Src = >4. Inhibition of serum-stimulated HUVEC cell proliferation data (IC₅₀ = μM) of compound I (R₁, R₂, R₅, R₆ = H; R₃, R₄ = Me; and R₇ = Et) against HUVEC = 0.009, A90 = 2.92, and C₆ = >25 uM was also provided. Metabolic stability and transport studies of compound I (R₁, R₂, R₅, R₆ = H; R₃, R₄ = Me; and R₇ = Et) with human and mice liver S9 preps. indicated half-lives > 200 min. Also investigated, the in vivo anticancer efficacy of compound I (R₁, R₂, R₅, R₆ = H; R₃, R₄ = Me; and R₇ = Et) against mammary adenocarcinoma M16/C: at 5 mg/kg dosage yielded a median mass of treated tumors/median mass of control tumor ratio of 39% with a net gain in subject body weight
- IT 185040-35-1P, 4-Ethylamino-2-methylsulfanylpyrimidine-5-carboxaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrido[2,3-d]pyrimidine-7-ones as antiangiogenic agents)
- RN 185040-35-1 HCPLUS
- CN 5-Pyrimidinecarboxaldehyde, 4-(ethylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)




- IT 5909-24-0, Ethyl 4-chloro-2-(methylthio)-5-pyrimidinecarboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)

(precursor; preparation of pyrido[2,3-d]pyrimidine-7-ones as antiangiogenic agents)

RN 5909-24-0 HCPLUS

CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT 144697-17-6, c-Src kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrido[2,3-d]pyrimidine-7-ones as antiangiogenic agents)

RN 144697-17-6 HCPLUS

CN Kinase (phosphorylating), gene c-src protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L23 ANSWER 4 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:47493 HCPLUS

DOCUMENT NUMBER: 132:175450

TITLE: Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy

AUTHOR(S): Dimitroff, Charles J.; Klohs, Wayne; Sharma, Amarnath; Pera, Paula; Driscoll, Denise; Veith, Jean; Steinkampf, Randall; Schroeder, Mel; Klutchko, Sylvester; Sumlin, Adam; Henderson, Barbara; Dougherty, Thomas J.; Bernacki, Ralph J.

CORPORATE SOURCE: Harvard Skin Disease Research Center, Harvard Medical School, Boston, MA, USA

SOURCE: Investigational New Drugs (1999), 17(2), 121-135

CODEN: INNDDK; ISSN: 0167-6997

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Angiogenesis, the formation of new blood vessels from an existing vasculature, is requisite for tumor growth. It entails intercellular coordination of endothelial and tumor cells through angiogenic growth factor signaling. Interruption of these events has implications in the suppression of tumor growth. PD166285, a broad-spectrum receptor tyrosine kinase (RTK) inhibitor, and PD173074, a selective FGFR1TK inhibitor, were evaluated for their anti-angiogenic activity and anti-tumor efficacy in combination with photodynamic therapy (PDT). To evaluate the anti-angiogenic and anti-tumor activities of these compds., RTK assays, in vitro tumor cell growth and microcapillary formation assays, in vivo murine angiogenesis and anti-tumor efficacy studies utilizing RTK inhibitors in combination with photodynamic therapy were performed. PD166285 inhibited PDGFR- β -, EGFR- and FGFR1TKs, and c-src TK by 50% (IC50) at concns. between 7-85 nM. PD173074 displayed selective inhibitory activity towards FGFR1TK at 26 nM. PD173074 demonstrated (> 100 fold) selective growth inhibitory action towards human umbilical vein

endothelial cells compared with a panel of tumor cell lines. Both PD166285 and PD173074 (at 10 nM) inhibited the formation of microcapillaries on Matrigel-coated plastic. In vivo anti-angiogenesis studies in mice revealed that oral administration (p.o.) of either PD166285 (1-25 mg/kg) or PD173074 (25-100 mg/kg) generated dose dependent inhibition of angiogenesis. Against a murine mammary 16c tumor, prolonged tumor regressions were achieved with daily p.o. doses of PD166285 (5-10 mg/kg) or PD173074 (30-60 mg/kg) following PDT compared with PDT alone. Many long-term survivors were also noted in combination treatment groups. PD166285 and PD173074 displayed potent anti-angiogenic and anti-tumor activity and prolonged the duration of anti-tumor response to PDT. Interference in membrane signal transduction by inhibitors of specific RTKs (e.g. FGFR1TK) should result in new chemotherapeutic agents having the ability to limit tumor angiogenesis and regrowth following cytoreductive treatments such as PDT.

IT 144697-17-6, c-Src tyrosine kinase
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
 (anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, in combination with photodynamic therapy)

RN 144697-17-6 HCAPLUS

CN Kinase (phosphorylating), gene c-src protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:764041 HCAPLUS

DOCUMENT NUMBER: 132:22971

TITLE: Preparation of oxopyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors

INVENTOR(S): Dobrusin, Ellen Myra; Hamby, James Marino; Kramer, James Bernard; Schroeder, Mel Conrad; Showalter, Howard Daniel Hollis; Toogood, Peter; Trumpp-Kallmeyer, Susanne A.

PATENT ASSIGNEE(S): Warner-Lambert Co.; USA

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961444	A2	19991202	WO 1999-US10187	19990510
WO 9961444	A3	20000203		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2329703	AA	19991202	CA 1999-2329703	19990510
AU 9940734	A1	19991213	AU 1999-40734	19990510
AU 763839	B2	20030731		
BR 9911590	A	20010213	BR 1999-11590	19990510

EP 1080092	A2	20010307	EP 1999-924165	19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200003429	T2	20010723	TR 2000-200003429	19990510
JP 2002516327	T2	20020604	JP 2000-550849	19990510
EE 200000706	A	20020617	EE 2000-706	19990510
NZ 508268	A	20040227	NZ 1999-508268	19990510
ZA 2000006536	A	20020211	ZA 2000-6536	20001110
BG 104960	A	20011031	BG 2000-104960	20001117
HR 2000000799	A1	20010630	HR 2000-799	20001120
NO 2000005928	A	20001123	NO 2000-5928	20001123
HK 1039483	A1	20040618	HK 2001-107828	20011108
US 2004044012	A1	20040304	US 2003-638848	20030811
PRIORITY APPLN. INFO.:			US 1998-86708P	P 19980526
			US 1999-126158P	P 19990325
			WO 1999-US10187	W 19990510
			US 2000-623737	A3 20000907

OTHER SOURCE(S) : MARPAT 132:22971
GI




AB Title compds. [I; G = NR₂ or CHR₂; R = NHR₁ or SOO-2R₁; R₁, R₂ = H, (cyclo)alkyl, (un)substituted PH, -pyridyl, etc.; R₃ = groups cited for R₁, OH, alkoxy(carbonyl), etc.; R₄ = H; R₃R₄ = bond; R₈, R₉ = H, halo, NH₂, alkoxy carbonyl, etc.; X = O, S, (alkyl)imino, etc.; Z = N or CH] were prepared as cyclin-dependant and tyrosine kinase inhibitors. Thus, 5-aminomethyl-4-cyclopentylamino-2-methylthiopyrimidine (preparation given) was cyclocondensed with 1,1'-carbonyldiimidazole and the oxidized product aminated by 4-(MeO)C₆H₄NH₂ to give I [G = cyclopentylimino, R = 4-(MeO)C₆H₄NH₂, R₃ = R₄ = R₈ = R₉ = H, X = O]. Data for biol. activity of I were given.


IT 770-31-0 5909-24-0 27431-62-5,
4-Diethylaminobutylamine 185040-35-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation)

RN 770-31-0 HCPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-(methylthio)- (6CI, 7CI, 8CI, 9CI)
(CA INDEX NAME)




RN 5909-24-0 HCPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 27431-62-5 HCPLUS
 CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 185040-35-1 HCPLUS
 CN 5-Pyrimidinecarboxaldehyde, 4-(ethylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)



L23 ANSWER 6 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:561587 HCPLUS
 DOCUMENT NUMBER: 131:184962
 TITLE: Preparation of oxidoamino-substituted
 pyrido[2,3-d]pyrimidines as protein tyrosine
 kinase inhibitors
 INVENTOR(S): Doherty, Annette Marian; Hallak, Hussein Osman;
 Hamby, James Marino
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA
 SOURCE: U.S., 25 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5945422	A	19990831	US 1998-15739	19980129
PRIORITY APPLN. INFO.:			US 1997-38822P	P 19970205
OTHER SOURCE(S):	MARPAT	131:184962		
GI				



AB Title compds. [I; R = ONR5R6Z1Z2NH; R1 = (un)substituted Ph or heteroaryl; R2 = H, (cyclo)alkyl, phenyl(alkyl), heteroaryl, etc.; R5,R6 = H, alkyl, phenyl(alkyl), etc.; R5R6 = atoms to complete a ring; X = O, S, (acyl)imino; Z1,Z2 = bond, alkylene(oxy), -(thio), arylene] were prepared Thus, I (R1 = C6H3C12-2,6, R2 = Me, X = O) (II; R = SMe) was aminated by Et2NCH2CH2OC6H4(NH2)-4 and the product oxidized to give II [R = 4-(ONEt2CH2CH2O)C6H4NH]. Data for biol.activity of I were given.

IT 100-46-9, Benzylamine, reactions 5909-24-0, Ethyl 4-chloro-2-methylthiopyrimidine-5-carboxylate 27431-62-5, 4-Diethylaminobutylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxidoamino-substituted pyrido[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)


RN 100-46-9 HCPLUS

CN Benzenemethanamine (9CI) (CA INDEX NAME)

H₂N—CH₂—Ph

RN 5909-24-0 HCPLUS

CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 27431-62-5 HCPLUS

CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

H₂N—(CH₂)₄—NET₂

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:139846 HCPLUS

DOCUMENT NUMBER: 130:196643

TITLE: Preparation of naphthyridinones as protein tyrosine kinase and cyclin dependant kinase inhibitors

INVENTOR(S): Barvian, Mark Robert; Denny, William Alexander;


Dobrusin, Ellen Myra; Hamby, James Marino;
 Showalter, Howard Daniel Hollis; Thompson, Andrew
 Mark; Winters, Roy Thomas; Wu, Zhipei

PATENT ASSIGNEE(S): Warner-Lambert Company, USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909030	A1	19990225	WO 1998-US16848	19980813
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2291222	AA	19990225	CA 1998-2291222	19980813
CA 2291222	C	20040330		
AU 9888289	A1	19990308	AU 1998-88289	19980813
AU 742999	B2	20020117		
EP 1003745	A1	20000531	EP 1998-939941	19980813
EP 1003745	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9811956	A	20000815	BR 1998-11956	19980813
JP 2001515078	T2	20010918	JP 2000-509710	19980813
NZ 502704	A	20020628	NZ 1998-502704	19980813
AT 286053	E	20050115	AT 1998-939941	19980813
ZA 9807491	A	19990421	ZA 1998-7491	19980819
MX 9911792	A	20000630	MX 1999-11792	19991215
US 6150359	A	20001121	US 2000-463553	20000126
PRIORITY APPLN. INFO.:			US 1997-56746P	P 19970820
			WO 1998-US16848	W 19980813

OTHER SOURCE(S): MARPAT 130:196643
 GI



AB Title compds. [I; R1 = halo or (un)substituted amino; R2 = (bi)(cyclo)alkyl; R5 = H, halo, (hetero)aryl, etc.; dashed line = optional bond] were prepared. Thus, 4,6-diamino-3-pyridinecarboxaldehyde (preparation given) was cyclocondensed with 2,6-C12C6H3CH2CN and the major product treated with NaNO2/HBF4 to give, after N-methylation, major product I (R2 = Me, R5 = C6H3Cl2-2,6) (II; R1 = F) which was aminated to give II (R1 =

IT e.g., NHMe). Data for biol. activity of I were given.
 IT 27431-62-5, 4-Diethylaminobutylamine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of naphthyridinones as protein tyrosine kinase and
 cyclin dependant kinase inhibitors)
 RN 27431-62-5 HCPLUS
 CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1998:724585 HCPLUS
 DOCUMENT NUMBER: 130:90084
 TITLE: Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
 AUTHOR(S): Mohammadi, Moosa; Froum, Scott; Hamby, James M.; Schroeder, Mel C.; Panek, Robert L.; Lu, Gina H.; Eliseenkova, Anna V.; Green, David; Schlessinger, Joseph; Hubbard, Stevan R.
 CORPORATE SOURCE: Departments of Pharmacology and Medicine, Kaplan Comprehensive Cancer Center, and Skirball Institute of Biomolecular Medicine, New York University Medical Center, New York, NY, 10016, USA
 SOURCE: EMBO Journal (1998), 17(20), 5896-5904
 CODEN: EMJODG; ISSN: 0261-4189
 PUBLISHER: Oxford University Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is an essential physiol. process in development, yet also plays a major role in the progression of human diseases such as diabetic retinopathy, atherosclerosis and cancer. The effects of the most potent angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell surface receptors that possess intrinsic protein tyrosine kinase activity. In this report, the authors describe a synthetic compound of the pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors. The authors show that systemic administration of PD 173074 in mice can effectively block angiogenesis induced by either FGF or VEGF with no apparent toxicity. To elucidate the determinants of selectivity, the authors have determined the crystal structure of PD 173074 in complex with the tyrosine kinase domain of FGF receptor 1 at 2.5 Å resolution. A high degree of surface complementarity between PD 173074 and the hydrophobic, ATP-binding pocket of FGF receptor 1 underlies the potency and selectivity of this inhibitor. PD 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the treatment of cancer and other diseases whose progression is dependent upon new blood vessel formation.


IT 62031-54-3, Fibroblast growth factor
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (crystal structure of an angiogenesis inhibitor bound to the

RN FGF receptor tyrosine kinase domain)
RN 62031-54-3 HCPLUS
CN Fibroblast growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 9 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:600713 HCPLUS
DOCUMENT NUMBER: 129:316187
TITLE: Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors
AUTHOR(S): Boschelli, Diane H.; Wu, Zhipei; Klutchko, Sylvester R.; Showalter, H. D. Hollis; Hamby, James M.; Lu, Gina H.; Major, Terry C.; Dahring, Tawny K.; Batley, Brian; Panek, Robert L.; Keiser, Joan; Hartl, Brian G.; Kraker, Alan J.; Klohs, Wayne D.; Roberts, Bill J.; Patmore, Sandra; Elliott, William L.; Steinkampf, Randy; Bradford, Laura A.; Hallak, Hussein; Doherty, Annette M.
CORPORATE SOURCE: Department of Medicinal Chemistry, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(22), 4365-4377
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (I) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of I with a 4-(N,N-diethylaminoethoxy)phenylamino group gave a compound, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogs that retained potency, including derivs. that were biased toward inhibition of the TK activity of PDGFr. Analogs of the 4-[(N,N-diethylaminoethoxy)phenylamino]-substituted derivative with a 3-thiophene or an unsubstituted Ph group at C-6 were the most potent inhibitors. One compound, 2-[4-[2-(diethylamino)ethoxy]phenylamino]-8-ethyl-6-phenyl-8H-pyrido[2,3-d]pyrimidin-7-one had IC₅₀ values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, resp... It was active in a variety of PDGF-dependent cellular assay and blocked the in vivo growth of three PDGF-dependent tumor lines.
IT 5909-24-0 185040-35-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and tyrosine kinase inhibitory activity of aminopyrido[2,3-d]pyrimidines)
RN 5909-24-0 HCPLUS
CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 185040-35-1 HCPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-(ethylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:496546 HCPLUS

DOCUMENT NUMBER: 129:211390

TITLE: 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity

AUTHOR(S): Klutchko, Sylvester R.; Hamby, James M.; Boschelli, Diane H.; Wu, Zhipei; Kraker, Alan J.; Amar, Aneesa M.; Hartl, Brian G.; Shen, Cynthia; Klohs, Wayne D.; Steinkampf, Randall W.; Driscoll, Denise L.; Nelson, James M.; Elliott, William L.; Roberts, Billy J.; Stoner, Chad L.; Vincent, Patrick W.; Dykes, Donald J.; Panek, Robert L.; Lu, Gina H.; Major, Terry C.; Dahring, Tawny K.; Hallak, Hussein; Bradford, Laura A.; Showalter, H. D. Hollis; Doherty, Annette M.

CORPORATE SOURCE: Departments of Chemistry Cancer Research Vascular and Cardiac Diseases and Pharmacokinetics and Drug Metabolism Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA

SOURCE: Journal of Medicinal Chemistry (1998), 41(17), 3276-3292

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB While engaged in therapeutic intervention against a number of proliferative diseases, we have discovered the 2-aminopyrido[2,3-d]pyrimidin-7(8H)-ones as a novel class of potent, broadly active tyrosine kinase (TK) inhibitors. An efficient route was developed that enabled the synthesis of a wide variety of analogs with substitution on several positions of the template. Compds. of this series were competitive with

ATP and displayed submicromolar to low nanomolar potency against a panel of TKs, including receptor (platelet-derived growth factor, PDGFr; fibroblast growth factor, FGFr; epidermal growth factor, EGFr) and nonreceptor (c-Src) classes. One of the more thoroughly evaluated members was 63 with IC₅₀ values of 0.079 μM (PDGFr), 0.043 μM (bFGFr), 0.044 μM (EGFr), and 0.009 μM (c-Src). In cellular studies, 63 inhibited PDGF-mediated receptor autophosphorylation in a number of cell lines at IC₅₀ values of 0.026-0.002 μM and proliferation of two PDGF-dependent lines at 0.3 μM. It also caused inhibition of soft agar colony formation in three cell lines that overexpress the c-Src TK, with IC₅₀ values of 0.33-1.8 μM. In in vivo studies against a panel of seven xenograft tumor models with known and/or inferred dependence on the EGFr, PDGFr, and c-Src TKs, compound 63 produced a tumor growth delay of 10.6 days against the relatively refractory SK-OV-3 ovarian xenograft and also displayed activity against the HT-29 tumor. In rat oral bioavailability studies, compound 63 plasma concns. declined in a biexponential manner, and systemic plasma clearance was high relative to liver blood flow. Finally, in rat metabolism studies, HPLC chromatog. identified two metabolites of 63. Because of the excellent potency of 63 against selected TKs, in vitro and in vivo studies are underway for this compound in addnl. tumor models dependent upon PDGFr, FGFr, and c-Src to assess its potential for advancement to clin. trials.

IT 144697-17-6, c-Src tyrosine kinase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (preparation of aminopyridopyrimidinones as tyrosine kinase inhibitors and anticancer agents)

RN 144697-17-6 HCPLUS

CN Kinase (phosphorylating), gene c-src protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 100-46-9, Benzylamine, reactions 5909-24-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aminopyridopyrimidinones as tyrosine kinase inhibitors and anticancer agents)

RN 100-46-9 HCPLUS

CN Benzenemethanamine (9CI) (CA INDEX NAME)

H₂N—CH₂—Ph


RN 5909-24-0 HCPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT 185040-35-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminopyridopyrimidinones as tyrosine kinase)

inhibitors and anticancer agents)

RN 185040-35-1 HCPLUS
 CN 5-Pyrimidinecarboxaldehyde, 4-(ethylamino)-2-(methylthio)- (9CI) (CA
 INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 11 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:202673 HCPLUS

DOCUMENT NUMBER: 128:257440

TITLE: Preparation of pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

INVENTOR(S): Blankley, Clifton John; Boschelli, Diane Harris; Doherty, Annette Marian; Hamby, James Marino; Klutchko, Sylvester; Panek, Robert Lee

PATENT ASSIGNEE(S): Warner-Lambert Company, USA
 SOURCE: U.S., 39 pp., Cont.-in-part of U.S. 5,620,981.


CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733914	A	19980331	US 1996-611279	19960403
US 5620981	A	19970415	US 1995-433294	19950503
IL 117923	A1	20000601	IL 1996-117923	19960416
CA 2214219	AA	19961107	CA 1996-2214219	19960426
WO 9634867	A1	19961107	WO 1996-US5819	19960426
W: AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9655769	A1	19961121	AU 1996-55769	19960426
AU 713727	B2	19991209		
EP 823908	A1	19980218	EP 1996-913175	19960426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1183099	A	19980527	CN 1996-193678	19960426
CN 1083452	B	20020424		
JP 11504922	T2	19990511	JP 1996-533372	19960426
NZ 307021	A	20010427	NZ 1996-307021	19960426
CZ 288160	B6	20010516	CZ 1997-3275	19960426
EE 3770	B1	20020617	EE 1997-274	19960426
PL 184093	B1	20020830	PL 1996-323089	19960426
SK 283952	B6	20040608	SK 1997-1410	19960426
ZA 9603486	A	19961113	ZA 1996-3486	19960502
NO 9705033	A	19971031	NO 1997-5033	19971031


NO 310110 B1 20010521 US 1995-433294 A2 19950503
 PRIORITY APPLN. INFO.: US 1996-611279 A 19960403
 WO 1996-US5819 W 19960426
 OTHER SOURCE(S) : MARPAT 128:257440
 GI




- AB The title compds. [I; X = NH, N-acyl, O, S; R1 = SOR3, SO2R3; R2, R3 = H, (CH₂)nPh (where Ph = (un)substituted phenyl; n = 0-3), heteroarom., etc.; Ar = (un)substituted Ph, heteroaryl], **inhibitors** of protein tyrosine **kinases**, and thus useful in treating cellular proliferation, especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis, were prepared and formulated. Thus, treatment of 2-ethoxyethanol with NaH followed by addition of 2,6-dimethylphenylacetonitrile, and 2-amino-4-methylamino-5-pyrimidinemcarboxaldehyde (preparation described) afforded pyrido[2,3-d]pyrimidine I [R1 = NH₂; R2 = Me; X = NH; Ar = 2,6-dimethylphenyl] which showed 42% **inhibition** of PDGFr-TK at 50 μM.
- IT 100-46-9, Benzylamine, reactions 5909-24-0
 27431-62-5, 4-(Diethylamino)butylamine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrido[2,3-d]pyrimidines for **inhibiting** protein tyrosine **kinase** mediated cellular proliferation)
- RN 100-46-9 HCPLUS
 CN Benzenemethanamine (9CI) (CA INDEX NAME)




- RN 5909-24-0 HCPLUS
 CN 5-Pyrimidinemcarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



- RN 27431-62-5 HCPLUS
 CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT 185040-35-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation)
 RN 185040-35-1 HCPLUS
 CN 5-Pyrimidinecarboxaldehyde, 4-(ethylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L23 ANSWER 12 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1998:202672 HCPLUS
 DOCUMENT NUMBER: 128:257439
 TITLE: Preparation of 6-arylpyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
 INVENTOR(S): Blankley, Clifton John; Doherty, Annette Marian; Hamby, James Marino; Panek, Robert Lee; Schroeder, Mel Conrad; Showalter, Howard Daniel Hollis; Connolly, Cleo
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 36 pp., Cont.-in-part of U.S. Ser. No. 339,051, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733913	A	19980331	US 1995-539410	19951106
CA 2199964	AA	19960523	CA 1995-2199964	19951113
WO 9615128	A2	19960523	WO 1995-US14700	19951113
W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9641078	A1	19960606	AU 1996-41078	19951113
AU 711426	B2	19991014		
EP 790997	A2	19970827	EP 1995-939129	19951113
EP 790997	B1	20000322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 76853	A2	19971229	HU 1997-1511	19951113
CN 1169726	A	19980107	CN 1995-196230	19951113
CN 1085666	B	20020529		
JP 10509452	T2	19980914	JP 1995-516240	19951113


CZ 286160	B6	20000112	CZ 1997-1390	19951113
AT 190978	E	20000415	AT 1995-939129	19951113
PT 790997	T	20000630	PT 1995-939129	19951113
ES 2146782	T3	20000816	ES 1995-939129	19951113
SK 281724	B6	20010710	SK 1997-609	19951113
PL 181893	B1	20011031	PL 1995-320169	19951113
MD 1861	F2	20020228	MD 1997-970187	19951113
RU 2191188	C2	20021020	RU 1997-110269	19951113
ZA 9509675	A	19960529	ZA 1995-9675	19951114
IL 115970	A1	19990620	IL 1995-115970	19951114
BG 63162	B1	20010531	BG 1997-101326	19970313
FI 9701953	A	19970512	FI 1997-1953	19970507
NO 9702198	A	19970513	NO 1997-2198	19970513
NO 308250	B1	20000821		
US 5952342	A	19990914	US 1998-40792	19980318
GR 3033439	T3	20000929	GR 2000-401126	20000518
PRIORITY APPLN. INFO.:			US 1994-339051	B2 19941114
			US 1995-539410	A 19951106
			WO 1995-US14700	W 19951113

OTHER SOURCE(S) : MARPAT 128:257439

GI



- AB The title compds. [I; R1, R2, R4 = H, C1-8 alkyl, C2-8 alkenyl, etc.; R3 = C(O)R8, CO2R8, C(S)R8, etc.; R8 = H, C1-8 alkyl, C2-8 alkenyl, etc.; Ar = (un)substituted aromatic or heteroarom. selected from Ph, imidazolyl, pyrrolyl, etc.], **inhibitors** of protein tyrosine **kinase** which are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections, were prepared and formulated. Thus, reaction of 2,7-diamino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidine (preparation described) with tert-Bu isocyanate in the presence of NaH in DMF afforded the urea I [R1 = R4 = H; R2 = R3 = C(O)NHTBu; Ar = 2,6-Cl2C6H3] which showed IC50 of 10.2 μ M against PDGF receptor tyrosine kinase.
- IT 5909-24-0 27431-62-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 6-arylpyrido[2,3-d]pyrimidines and naphthyridines for **inhibiting** protein tyrosine **kinase** mediated cellular proliferation)
- RN 5909-24-0 HCPLUS
- CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 27431-62-5 HCAPLUS
 CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

H₂N—(CH₂)₄—NET₂

IT 770-31-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 6-arylpyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation)

RN 770-31-0 HCAPLUS
 CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-(methylthio)- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:686365 HCAPLUS

DOCUMENT NUMBER: 127:355051

TITLE: Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

AUTHOR(S): Connolly, Cleo J. C.; Hamby, James

M.; Schroeder, Mel C.; Barvian, Mark;
 Lu, Gina H.; Panek, Robert L.; Amar, Aneesa; Shen,
 Cindy; Kraker, Alan J.; Fry, David W.; Klohs, Wayne
 D.; Doherty, Annette M.

CORPORATE SOURCE: Division of Warner-Lambert Company, Department of Chemistry, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 48105, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(18), 2415-2420

CODEN: BMCL8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 127:355051

AB The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGF_r, and c-Src tyrosine kinases was developed from compound library screening and lead optimization. In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biol. evaluation, and structure-activity relationships of this series are reported.

IT 144697-17-6, c-Src tyrosine kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(discovery and structure-activity studies of a novel series of pyrido[d]pyrimidine tyrosine kinase inhibitors)

RN 144697-17-6 HCAPLUS

CN Kinase (phosphorylating), gene c-src protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:436125 HCAPLUS

DOCUMENT NUMBER: 127:117061

TITLE: Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors

AUTHOR(S): Hamby, James M.; Connolly, Cleo J.

C.; Schroeder, Mel C.; Winters, R.

Thomas; Showalter, H. D. Hollis; Panek, Robert L.; Major, Terry C.; Olsewski, Bronislawa; Ryan, Michael J.; Dahring, Tawny; Lu, Gina H.; Keiser, Joan; Amar, Aneesa; Shen, Cindy; Kraker, Alan J.; Slintak, Veronika; Nelson, James M.; Fry, David W.; Bradford, Laura; Hallak, Hussein; Doherty, Annette M.

CORPORATE SOURCE: Parke-Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI, 48105, USA

SOURCE: Journal of Medicinal Chemistry (1997), 40(15), 2296-2303

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Screening of a compound library for inhibitors of the fibroblast growth factor (FGFr) and platelet-derived growth factor (PDGFr) receptor tyrosine kinases led to the development of a novel series of ATP competitive pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. The initial lead, 1-[2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea (I; PD-089828), was found to be a broadly active tyrosine kinase inhibitor. I inhibited the PDGFr, FGFr, EGFr, and c-src tyrosine kinases with IC₅₀ values of 1.11, 0.13, 0.45, and 0.22 μM, resp. Subsequent SAR studies led to the synthesis of new analogs with improved potency, solubility, and bioavailability relative to the initial lead. For example, the introduction of a [4-(diethylamino)butyl]amino side chain into the 2-position of I afforded a compound (II) with enhanced potency and bioavailability. II inhibited PDGF-stimulated vascular smooth muscle cell proliferation with an IC₅₀ of 0.3 μM.

Furthermore, replacement of the 6-(2,6-dichlorophenyl) moiety of I with a 6-(3',5'-dimethoxyphenyl) functionality produced a highly selective FGFr tyrosine kinase inhibitor (III). III

inhibited the FGFr tyrosine kinase with an IC₅₀ of 0.060 μM, whereas IC₅₀s for the inhibition of the PDGFr, FGFr, EGFr, c-src, and InsR tyrosine kinases for this compound were all greater than 50 μM.

IT 144697-17-6, c-Src tyrosine kinase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (pyrido[2,3-d]pyrimidine tyrosine kinase inhibitor preparation and structure-activity relationship)

RN 144697-17-6 HCAPLUS
 CN Kinase (phosphorylating), gene c-src protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 27431-62-5, 4-(Diethylaminobutylamine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction; pyrido[2,3-d]pyrimidine tyrosine kinase inhibitor preparation and structure-activity relationship)

RN 27431-62-5 HCAPLUS
 CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

H₂N—(CH₂)₄—NET₂

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:407661 HCAPLUS

DOCUMENT NUMBER: 127:130930

TITLE: Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 08928, a new synthetic protein tyrosine kinase inhibitor

AUTHOR(S): Dahring, Tawny K.; Lu, Gina H.; Hamby, James M.; Batley, Brian L.; Kraker, Alan J.; Panek, Robert L.

CORPORATE SOURCE: Departments of Vascular and Cardiac Diseases, Chemistry and Cancer Research, Division of Warner-Lambert Company, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 48105, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (1997), 281(3), 1446-1456

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB PD 089828, a novel protein tyrosine kinase inhibitor of a new structural class, the 6-aryl-pyrido-[2,3-d]pyrimidines, was identified by screening a compound library with assays that measured protein tyrosine kinase activity. PD 089828 was found to inhibit human full-length fibroblast growth factor (FGF) receptor-1 (FGFR-1), platelet-derived growth factor (PDGF) receptor β subunit (PDGFR-β), Src nonreceptor tyrosine kinase (c-Src) and epidermal growth factor (EGF) receptor (EGFR) tyrosine kinases with half-maximal inhibitory potencies (IC₅₀ values) of 0.15,

0.18, 1.76 and 5.47 μM , resp. PD 089828 was further characterized as an ATP competitive **inhibitor** of the growth factor receptor tyrosine **kinases** (FGFR-1, PDGFR- β and EGFR) but a noncompetitive **inhibitor** of c-Src tyrosine **kinase** with respect to ATP. In addition, PD 089828 **inhibited** PDGF- and EGF-stimulated receptor autophosphorylation in vascular smooth muscle cells (VSMC) and basic FGF-mediated tyrosine phosphorylation in A121 cells with IC₅₀ values similar to the potencies observed for **inhibitor** of receptor tyrosine **kinase** activity. The **inhibition** of PDGF receptor autophosphorylation in VSMC by PD 089828 occurred rapidly, with maximal effects reached within 5 min of drug exposure. **Inhibition** after single exposure was long lasting but also rapidly reversible, occurring within 5 min after drug removal. The PDGF-induced association of downstream signaling proteins, including phosphoinositide-3-**kinase** (PI-3K), growth factor receptor binding protein-2 (GRB2), SH-2 domain and collagen like (Shc) and phospholipase C γ (PLC γ), with VSMC PDGF receptors was also blocked as a result of the **inhibition** of PDGF-stimulated receptor autophosphorylation by PD 089828. PD 089828 also **inhibited** the PDGF-induced tyrosine phosphorylation of the 44- and 42-kDa mitogen-activated protein **kinase** isoforms. Moreover, the effects of PD 089828 were demonstrated in functional assays in which PDGF-stimulated DNA synthesis, PDGF-directed migration and serum-stimulated growth of VSMC were all **inhibited** to the same extent as PDGF receptor autophosphorylation (IC₅₀ = 0.8, 4.5 and 1.8 μM , resp.). These results highlight the biol. characteristics of PD 089828 as a novel, broadly active protein tyrosine **kinase inhibitor** with long-lasting but reversible cellular effects. The potential therapeutic use of these broadly acting, nonselective **inhibitors** as antiproliferative and antimigratory agents could extend to such diseases as cancer, atherosclerosis and restenosis in which redundancies in growth-signaling pathways are known to exist.

IT 144697-17-6, c-Src tyrosine kinase 147014-97-9
, Cyclin-dependent **kinase-4**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**inhibition** of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by new synthetic protein tyrosine **kinase inhibitor** PD 08928 in relation to potential therapeutic use)

RN 144697-17-6 HCPLUS
CN Kinase (phosphorylating), gene c-src protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 147014-97-9 HCPLUS
CN Kinase (phosphorylating), protein p33CDK4 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L23 ANSWER 16 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:26258 HCPLUS
DOCUMENT NUMBER: 126:59965
TITLE: Preparation of pyrido[2,3-d]pyrimidines as protein tyrosine **kinase** mediated cell proliferation **inhibitors**
INVENTOR(S): Blankley, Clifton John; Boschelli, Diane Harris;
Doherty, Annette Marian; Hamby, James Marino
; Klutchko, Sylvester; Panek, Robert Lee
PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 147 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9634867	A1	19961107	WO 1996-US5819	19960426
W: AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5620981	A	19970415	US 1995-433294	19950503
US 5733914	A	19980331	US 1996-611279	19960403
AU 9655769	A1	19961121	AU 1996-55769	19960426
AU 713727	B2	19991209		
EP 823908	A1	19980218	EP 1996-913175	19960426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 11504922	T2	19990511	JP 1996-533372	19960426
NZ 307021	A	20010427	NZ 1996-307021	19960426
EE 3770	B1	20020617	EE 1997-274	19960426
PL 184093	B1	20020830	PL 1996-323089	19960426
SK 283952	B6	20040608	SK 1997-1410	19960426
NO 9705033	A	19971031	NO 1997-5033	19971031
NO 310110	B1	20010521		
PRIORITY APPLN. INFO.:			US 1995-433294	A 19950503
			US 1996-611279	A 19960403
			WO 1996-US5819	W 19960426

OTHER SOURCE(S) : MARPAT 126:59965
GI


AB Title compds. [I; R = (un)substituted Ph or heteroaryl; R1 = NR3R4, SOO-2R3, OR3; R2-R4 = H, alkyl, (CH2)0-3Ph, heteroaryl, etc.; R4 may addnl. = COR3, CO2R3, SO2R3, etc.; NR3R4 = atoms to form a ring; X = O, S, (acyl)imino] were pred. Thus, EtOCH:C(CN)CO2Et was cyclocondensed with MeSC(:NH)NH2 and the product converted in 5 steps to 2-amino-4-methylamino-5-pyrimidinecarboxaldehyde which was cyclocondensed with 2,6-Me2C6H3CH2CN to give I (R = 2,6-Me2C6H3, R1 = NH2, R2 = Me, X = NH). Data for biol. activity of I were given.

IT 100-46-9, Benzylamine, reactions 5909-24-0
27431-62-5, 4-Diethylaminobutylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrido[2,3-d]pyrimidines as protein tyrosine kinase mediated cell proliferation inhibitors)

RN 100-46-9 HCPLUS
CN Benzenemethanamine (9CI) (CA INDEX NAME)

H₂N—CH₂—Ph


RN 5909-24-0 HCPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 27431-62-5 HCPLUS
 CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

H₂N—(CH₂)₄—NEt₂

IT 185040-35-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrido[2,3-d]pyrimidines as protein tyrosine kinase mediated cell proliferation inhibitors)
 RN 185040-35-1 HCPLUS
 CN 5-Pyrimidinecarbaldehyde, 4-(ethylamino)-2-(methylthio)- (9CI) (CA INDEX NAME)



L23 ANSWER 17 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1996:467130 HCPLUS
 DOCUMENT NUMBER: 125:114688
 TITLE: Preparation of 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase-mediated cellular proliferation
 INVENTOR(S): Blankley, Clifton John; Doherty, Annette Marian;
 Hamby, James Marino; Panek, Robert Lee;
 Schroeder, Mel Conrad; Showalter, Howard
 Daniel Hollis; Connolly, Cleo
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA
 SOURCE: PCT Int. Appl., 134 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9615128	A2	19960523	WO 1995-US14700	19951113
W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5733913	A	19980331	US 1995-539410	19951106
AU 9641078	A1	19960606	AU 1996-41078	19951113
AU 711426	B2	19991014		
EP 790997	A2	19970827	EP 1995-939129	19951113
EP 790997	B1	20000322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10509452	T2	19980914	JP 1995-516240	19951113
AT 190978	E	20000415	AT 1995-939129	19951113
SK 281724	B6	20010710	SK 1997-609	19951113
PL 181893	B1	20011031	PL 1995-320169	19951113
MD 1861	F2	20020228	MD 1997-970187	19951113
RU 2191188	C2	20021020	RU 1997-110269	19951113
BG 63162	B1	20010531	BG 1997-101326	19970313
FI 9701953	A	19970512	FI 1997-1953	19970507
NO 9702198	A	19970513	NO 1997-2198	19970513
NO 308250	B1	20000821		
GR 3033439	T3	20000929	GR 2000-401126	20000518
PRIORITY APPLN. INFO.:			US 1994-339051	A 19941114
			US 1995-539410	A 19951106
			WO 1995-US14700	W 19951113

OTHER SOURCE(S) :

MARPAT 125:114688

GI




- AB 6-Arylpyrido[2,3-d]pyrimidines and naphthyridines I [X = CH, N; B = halo, OH, NR3R4; R1, R2, R3, R4 = H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, Ar', amino, C1-8 alkylamino, di-C1-8 alkylamino, wherein the alkyl, alkenyl, and alkynyl groups may be substituted by amino, OH, or 5- or 6-membered carbocyclic or heterocyclic ring; Ar, Ar' = (un)substituted aromatic or heteroarom. groups; R1R2N or R3R4N can complete a ring having 3-6 C atoms and optionally containing 1 or 2 heteroatoms; when X = N and B = NR3R4, one of R3 and R4 ≠ H] or their pharmaceutically acceptable acid and base addition salts, useful as **inhibitors** of protein tyrosine **kinase** and thus useful in treating cellular proliferation mediated thereby, are claimed. The compds. are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections. In an example, the IC50 of I [X = N, B = NHCONH2, R1 = H, R2 = Et2N(CH2)4 Ar = 2,6-C12C6H3; preparation given] for **inhibition** of protein tyrosine **kinases** was 0.231 μM for PDGF and 0.0954 for FGF.
- IT 5909-24-0, Ethyl 4-chloro-2-methylthio-5-pyrimidinecarboxylate
27431-62-5, 4-(Diethylamino)butylamine

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aryl pyridopyrimidines and naphthyridines for
 inhibiting protein tyrosine kinase-mediated cellular
 proliferation)


RN 5909-24-0 HCPLUS

CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-(methylthio)-, ethyl ester (6CI,
 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 27431-62-5 HCPLUS

CN 1,4-Butanediamine, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




IT 770-31-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of aryl pyridopyrimidines and naphthyridines for
 inhibiting protein tyrosine kinase-mediated cellular
 proliferation)

RN 770-31-0 HCPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-(methylthio)- (6CI, 7CI, 8CI, 9CI)
 (CA INDEX NAME)





=> d ibib abs hitstr 127 1-12

L27 ANSWER 1 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:120672 HCPLUS
 DOCUMENT NUMBER: 142:198094
 TITLE: Preparation of pyrimidopyrimidines as protein kinase inhibitors
 INVENTOR(S): Sim, Taebo; Lee, Hyun Soo; Ren, Pingda; Ding, Qiang;
 Wang, Xia; Uno, Tetsuo; Zhang, Guobao; Liu, Yi; Li, Bing; Li, Lintong; Gray, Nathaniel; You, Shuli
 PATENT ASSIGNEE(S): IRM LLC, Bermuda
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011597	A2	20050210	WO 2004-US24764	20040729
WO 2005011597	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-491133P P 20030729
 OTHER SOURCE(S): MARPAT 142:198094
 GI



AB The invention provides a novel class of compds. I [$n = 0-4$; $Z = N, CH$; $R1 = H, alkyl, arylalkyl, hydroxy, alkoxy, etc.$; $R2, R3 = H, alkyl$; or $R1$ and $R2$ together form O or S; $R4 = H, OH, NH2, alkyl, etc.$; $R5 = alkyl, alkenyl, alkoxy, etc.$; $R6 = NR12Y(O)R13, Y(O)NR12R13$ (wherein $Y = C, P(O), S(O)$; $R12 = H, alkyl$; $R13 = aryl, heteroaryl, cycloalkyl, etc.$)], pharmaceutical compns. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases. E.g., a multi-step synthesis of II, starting from 4-amino-2-methylsulfanylpyrimidine-5-carbonitrile, was given. The compds. I show a percentage inhibition of greater than 50% against the mentioned above kinases at 10 μM .

IT

839705-51-0P 839705-52-1P 839705-53-2P
 839705-54-3P 839705-55-4P 839705-56-5P
 839705-57-6P 839705-58-7P 839705-59-8P
 839705-60-1P 839705-61-2P 839705-62-3P
 839705-63-4P 839705-64-5P 839705-65-6P
 839705-66-7P 839705-67-8P 839705-69-0P
 839705-70-3P 839705-71-4P 839705-72-5P
 839705-73-6P 839705-74-7P 839705-75-8P
 839705-76-9P 839705-77-0P 839705-78-1P
 839705-79-2P 839705-80-5P 839705-81-6P
 839705-82-7P 839705-83-8P 839705-84-9P
 839705-85-0P 839705-86-1P 839705-87-2P
 839705-88-3P 839705-89-4P 839705-90-7P
 839705-91-8P 839705-92-9P 839705-93-0P
 839705-94-1P 839705-95-2P 839705-97-4P
 839705-98-5P 839705-99-6P 839706-00-2P
 839706-01-3P 839706-02-4P 839706-03-5P

839706-04-6P 839706-05-7P 839706-06-8P
839706-07-9P 839706-08-0P 839706-09-1P
839706-10-4P 839706-11-5P 839706-12-6P
839706-13-7P 839706-14-8P 839706-15-9P
839706-16-0P 839706-17-1P 839706-18-2P
839706-19-3P 839706-20-6P 839706-21-7P
839706-22-8P 839706-23-9P 839706-24-0P
839706-25-1P 839706-26-2P 839706-27-3P
839706-28-4P 839706-29-5P 839706-30-8P
839706-31-9P 839706-32-0P 839706-33-1P
839706-34-2P 839706-35-3P 839706-36-4P
839706-37-5P 839706-38-6P 839706-39-7P
839706-40-0P 839706-41-1P 839706-42-2P
839706-43-3P 839706-44-4P 839706-45-5P
839706-46-6P 839706-47-7P 839706-48-8P
839706-49-9P 839706-50-2P 839706-51-3P
839706-52-4P 839706-53-5P 839706-54-6P
839706-55-7P 839706-56-8P 839706-57-9P
839706-58-0P 839706-59-1P 839706-60-4P
839706-61-5P 839706-62-6P 839706-63-7P
839706-64-8P 839706-65-9P 839706-66-0P
839706-67-1P 839706-68-2P 839706-69-3P
839706-70-6P 839706-71-7P 839706-72-8P
839706-73-9P 839706-74-0P 839706-75-1P
839706-76-2P 839706-77-3P 839706-78-4P
839706-79-5P 839706-80-8P 839706-81-9P
839706-82-0P 839706-83-1P 839706-84-2P
839706-85-3P 839706-86-4P 839706-87-5P
839706-88-6P 839706-89-7P 839706-90-0P
839706-91-1P 839706-93-3P 839706-94-4P
839706-96-6P 839706-97-7P 839706-98-8P
839706-99-9P 839707-00-5P 839707-01-6P
839707-02-7P 839707-03-8P 839707-04-9P
839707-05-0P 839707-06-1P 839707-07-2P
839707-08-3P 839707-09-4P 839707-10-7P
839707-11-8P 839707-12-9P 839707-13-0P
839707-14-1P 839707-15-2P 839707-16-3P
839707-17-4P 839707-18-5P 839707-19-6P
839707-20-9P 839707-21-0P 839707-22-1P
839707-23-2P 839707-24-3P 839707-25-4P
839707-26-5P 839707-27-6P 839707-28-7P
839707-29-8P 839707-30-1P 839707-31-2P
839707-32-3P 839707-33-4P 839707-34-5P
839707-35-6P 839707-36-7P 839707-37-8P
839707-38-9P 839707-39-0P 839707-40-3P
839707-41-4P 839707-43-6P 839707-44-7P
839707-45-8P 839707-46-9P 839707-47-0P
839707-48-1P 839707-49-2P 839707-50-5P
839707-53-8P 839707-54-9P 839707-55-0P
839707-56-1P 839707-57-2P 839707-58-3P
839707-59-4P 839707-60-7P 839707-61-8P
839707-62-9P 839707-63-0P 839707-64-1P
839707-65-2P 839707-66-3P 839707-67-4P
839707-68-5P 839707-69-6P 839707-70-9P
839707-71-0P 839707-72-1P 839707-73-2P
839707-74-3P 839707-75-4P 839707-76-5P
839707-77-6P 839707-78-7P 839707-79-8P
839707-80-1P 839707-81-2P 839707-82-3P
839707-83-4P 839707-84-5P 839707-85-6P

839707-86-7P 839707-87-8P 839708-01-9P


839708-02-0P 839708-03-1P 839708-08-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidines as protein kinase inhibitors)


RN 839705-51-0 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(phenylmethyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-52-1 HCPLUS

CN Benzamide, N-[3-[7-[[3-[(aminocarbonyl)amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-53-2 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-54-3 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 $\rightarrow CF_3$


RN 839705-55-4 HCPLUS

CN Benzamide, N-[3-[7-[(3-(aminosulfonyl)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-56-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(3-(2-hydroxyethyl)phenyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-57-6 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-(4-methyl-1-piperazinyl)phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-58-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-phenylhydrazino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-59-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[3-[(hydroxyacetyl)amino]phenyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-60-1 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4H-1,2,4-triazol-4-ylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-61-2 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(4-methyl-1-piperazinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839705-62-3 HCPLUS

CN Benzamide, N-[3-[7-[(3-(formylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839705-63-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839705-64-5 HCPLUS

CN Benzamide, N-[3-[7-(cyclopropylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839705-65-6 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(2-hydroxyethyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839705-66-7 HCPLUS


CN Benzamide, N-[3-[7-[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-(2-hydroxyethyl)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839705-67-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[2-[(1-methylethyl)amino]ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—CF₃


RN 839705-69-0 HCPLUS
 CN Benzoic acid, 3-[[5,6,7,8-tetrahydro-8-methyl-6-[2-methyl-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 839705-70-3 HCPLUS
 CN Benzamide, N-[3-[7-(cyclobutylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-71-4 HCPLUS
 CN Benzamide, N-[3-[7-(cyclopentylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-72-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(1S)-2-hydroxy-1-methylethyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839705-73-6 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-7-[(1R)-2-hydroxy-1-methylethyl]amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839705-74-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-propenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-75-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(2-methyl-2-propenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-76-9 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[3-(2-oxo-1-pyrrolidinyl)propyl]aminol]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-77-0 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—NMe₂

RN 839705-78-1 HCPLUS
 CN Benzamide, 3-(dimethylamino)-N-[3-[7-[(3-[(dimethylamino)methyl]phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-79-2 HCPLUS
 CN Benzamide, N-[3-[7-[(3-[(2-dimethylamino)ethyl]phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-80-5 HCPLUS
 CN Benzamide, N-[3-[7-[(3-[(2-aminoethyl)amino]phenyl)amino]-1,4-dihydro-1-

methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 $\longrightarrow \text{CF}_3$

RN 839705-81-6 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[2-(methylamino)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-82-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃

RN 839705-83-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃


RN 839705-84-9 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[2-(methylamino)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-85-0 HCPLUS


CN Benzamide, N-[3-[7-[[4-(2-aminoethyl)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-86-1 HCPLUS
 CN Benzamide, N-[3-[(3-(2-aminoethyl)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-87-2 HCPLUS
 CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(3-(4-morpholinylmethyl)phenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-88-3 HCPLUS
 CN Benzamide, N-[3-[(1,4-dihydro-7-[(3-(1H-imidazol-1-yl)propyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839705-89-4 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(3-[2-(1-piperazinyl)ethyl]phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- CF₃

RN 839705-90-7 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(4-[2-(1-piperazinyl)ethyl]phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- CF₃


RN 839705-91-8 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-methyl-5-isoxazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839705-92-9 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[3-(1-piperazinylmethyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-93-0 HCAPLUS

CN Benzamide, N-[3-[7-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-94-1 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[4-(1-piperazinyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839705-95-2 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839705-97-4 HCPLUS

CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839705-98-5 HCPLUS


CN Benzamide, N-[3-[7-[(6-ethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839705-99-6 HCPLUS
 CN Benzamide, N-[3-[7-[(6-ethenyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-00-2 HCPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(6-(trifluoromethyl)-3-pyridinyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839706-01-3 HCPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[6-[2-(4-morpholinyl)ethyl]-3-pyridinyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 --CF_3


RN 839706-02-4 HCPLUS

CN Benzamide, N-[3-[(6-[(diethylamino)ethyl]-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-03-5 HCPLUS

CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-04-6 HCPLUS

CN Benzamide, N-[3-[7-[(4-fluorophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-05-7 HCPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-06-8 HCPLUS

CN Benzamide, N-[3-[1-cyclopropyl-7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-07-9 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-08-0 HCAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 839706-09-1 HCAPLUS
 CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4-piperidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-10-4 HCAPLUS
 CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[3-(trifluoromethyl)benzoyl]amino]phenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-11-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-N-methyl-7-[(6-methyl-3-pyridinyl)amino]-3-[2-methyl-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-12-6 HCAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-7-[(4-fluorophenyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-13-7 HCAPLUS

CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-ethenylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-14-8 HCAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(3-methyl-5-isoxazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-15-9 HCAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-(4-morpholinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-16-0 HCAPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

_CF₃

RN 839706-17-1 HCAPLUS
 CN Benzamide, N-[3-[1-cyclopropyl-7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-18-2 HCAPLUS
 CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-19-3 HCAPLUS
 CN Benzamide, N-[3-[1-cyclopropyl-7-[(4,6-dimethyl-3-pyridinyl)amino]-1,4-

dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-20-6 HCPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-21-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[(4-(trifluoromethyl)phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-22-8 HCPLUS

CN Benzamide, N-[3-[1-cyclopropyl-1,4-dihydro-2-oxo-7-[(4-(trifluoromethyl)phenyl)amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-23-9 HCPLUS

CN Benzamide, N-[3-[7-(ethylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-24-0 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-25-1 HCPLUS

CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-26-2 HCPLUS

CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-27-3 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-28-4 HCPLUS

CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-ethylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-29-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-30-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-31-9 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-32-0 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-33-1 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-

dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-34-2 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-35-3 HCPLUS

CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-36-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-37-5 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-38-6 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-39-7 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-40-0 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-41-1 HCAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-42-2 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-43-3 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-44-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-45-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-46-6 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-47-7 HCAPLUS

CN 3-Pyridinecarboxamide, N-[3-[1,4-dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-1,2-dihydro-2-oxo-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-48-8 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-(9CI) (CA INDEX NAME)




RN 839706-49-9 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-(methylamino)-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-50-2 HCPLUS

CN Benzamide, N-[3-[7-(ethylamino)-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-51-3 HCPLUS

CN Benzamide, N-[3-[7-(cyclopropylamino)-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-52-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methyl-2-propenyl)amino]-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-53-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-54-6 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-[[4-(4-morpholinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-55-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-(methylamino)-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-56-8 HCPLUS

CN Benzamide, N-[3-[7-(ethylamino)-1,4-dihydro-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-57-9 HCPLUS

CN Benzamide, N-[3-[7-(cyclopropylamino)-1,4-dihydro-2-oxo-1-[2-(2-pyridinyl)ethyl]pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-58-0 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-59-1 HCPLUS


CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-60-4 HCPLUS


CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(1-methylethyl)amino]-2-

oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-61-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 839706-62-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-N-methyl-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-63-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3,4-dihydro-3-[3-methoxy-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-64-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-65-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, N-ethyl-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-66-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N,N-dimethyl-7-(methylamino)-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-67-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, N-cyclopropyl-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-2-oxo-(9CI) (CA INDEX NAME)




RN 839706-68-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-hydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-7-(methylamino)-N-(1-methylethyl)-2-oxo-(9CI) (CA INDEX NAME)




RN 839706-69-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-(ethylamino)-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-2-oxo-(9CI) (CA INDEX NAME)




RN 839706-70-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-[(1,3-dimethyl-1*H*-pyrazol-5-yl)amino]-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-71-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 7-[(4,6-dimethyl-3-pyridinyl)amino]-3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-72-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3,4-dihydro-3-[3-methoxy-5-[(3-(trifluoromethyl)benzoyl)amino]phenyl]-N-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxo- (9CI) (CA INDEX NAME)




RN 839706-73-9 HCAPLUS

CN Benzamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-74-0 HCAPLUS


CN Benzamide, N-[3-(7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-75-1 HCAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me


RN 839706-76-2 HCPLUS

CN Benzamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-77-3 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-78-4 HCPLUS

CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-79-5 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(1-methylethyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-80-8 HCPLUS

CN Benzamide, N-[3-[7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-81-9 HCPLUS

CN Acetamide, N-[3-[1-ethyl-1,4-dihydro-7-[[4-(4-morpholinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-82-0 HCAPLUS

CN Acetamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-83-1 HCAPLUS

CN Acetamide, N-[3-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-84-2 HCAPLUS

CN Acetamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-85-3 HCPLUS

CN Acetamide, N-[3-[7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-2,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 839706-86-4 HCPLUS

CN Benzamide, N-[3-[1-ethyl-7-[(1-ethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-87-5 HCPLUS

CN Benzamide, N-[3-[7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-88-6 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839706-89-7 HCPLUS

CN Benzamide, N-[3-[7-[(4,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839706-90-0 HCPLUS


CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839706-91-1 HCPLUS


CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-

(9CI) (CA INDEX NAME)




RN 839706-93-3 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(2-methyl-4-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839706-94-4 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839706-96-6 HCPLUS

CN Benzamide, N-[3-[7-[[4-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 839706-97-7 HCPLUS

CN Benzamide; N-[3-[7-[(5-[(dimethylamino)methyl]-2-thiazolyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839706-98-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 --CF_3


RN 839706-99-9 HCPLUS

CN Benzamide, N-[3-[7-[(4-[(dimethylamino)methyl]phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-00-5 HCPLUS

CN Benzamide, N-[3-[7-[(3-cyanophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-01-6 HCPLUS

CN Benzamide, N-[3-[7-[(5-cyano-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-02-7 HCPLUS

CN Benzamide, N-[3-[7-[(2,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-03-8 HCPLUS

CN Benzamide, N-[3-[7-[(4,6-dimethyl-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-04-9 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(4-methoxy-3-pyridinyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-05-0 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(2-methoxy-3-pyridinyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-06-1 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(2-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-07-2 HCAPLUS

CN Benzamide, N-[3-[7-[(2,4-dimethyl-5-thiazolyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-08-3 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-09-4 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1,4-dimethyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-10-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1,4-dimethyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-11-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1,4-dimethyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-12-9 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-(methylamino)-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839707-13-0 HCAPLUS


CN Benzamide, N-[3-[7-amino-1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839707-14-1 HCAPLUS


CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-

d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-15-2 HCPLUS


CN Benzamide, N-[3-[7-(ethylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-16-3 HCPLUS

CN Benzamide, N-[3-[7-[4-[2-(diethylamino)ethoxy]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

CF₃


RN 839707-17-4 HCPLUS

CN Benzamide, N-[3-(7-amino-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-18-5 HCAPLUS

CN Benzamide, N-[3-[1-ethyl-7-(ethylamino)-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-19-6 HCAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[3-(4-morpholinyl)propyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-20-9 HCAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[4-(4-morpholinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-21-0 HCAPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-22-1 HCPLUS

CN Benzamide, N-[3-[7-(cyclopropylamino)-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-23-2 HCPLUS

CN Benzamide, N-[3-[1-ethyl-1,4-dihydro-7-[(2-methyl-2-propenyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-24-3 HCPLUS

CN Benzamide, N-[3-[7-[[3-(diethylamino)propyl]amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-25-4 HCPLUS

CN Benzamide, N-[3-[7-[[4-(diethylamino)butyl]amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-26-5 HCPLUS

CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-5-methoxyphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-27-6 HCPLUS

CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-nitro-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839707-28-7 HCPLUS

CN Benzamide, 3-amino-N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-29-8 HCPLUS

CN Benzamide, N-[3-[7-[[3-[(2S)-2-amino-1-oxopropyl]amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 --CF_3

RN 839707-30-1 HCPLUS


CN Benzamide, N-[3-[7-[[3-[(2S)-2-amino-3-methyl-1-oxobutyl]amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 839707-31-2 HCPLUS

CN Benzamide, N-[3-[7-[[6-[3-(dimethylamino)-1-pyrrolidinyl]-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-32-3 HCAPLUS

CN Benzamide, N-[3-[7-[(6-[(2-(dimethylamino)ethyl)methylamino]-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-B

—CF₃

RN 839707-33-4 HCAPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(2-pyrimidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839707-34-5 HCAPLUS


CN Benzamide, N-[3-[7-[(5,6-dimethyl-1,2,4-triazin-3-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839707-35-6 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(pyrazinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 839707-36-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-methyl-5-isothiazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-37-8 HCPLUS

CN Benzamide, N-[3-[7-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839707-38-9 HCAPLUS


CN Benzamide, N-[3-[7-[(1-ethyl-1H-pyrazol-5-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839707-39-0 HCAPLUS

CN Benzamide, N-[3-[7-[(2-dimethylamino)-1-methylethoxy]-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃

RN 839707-40-3 HCPLUS

CN Benzamide, N-[3-[7-[(4-(diethylamino)ethoxy)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 --CF_3


RN 839707-41-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-(4-methyl-1-piperazinyl)propyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-43-6 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(4-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-44-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(3-methyl-4-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-45-8 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[5-(4-morpholinylmethyl)-3-pyridinyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-46-9 HCPLUS

CN Benzamide, N-[3-[7-[[6-(diethylamino)-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-47-0 HCPLUS


CN Benzamide, N-[3-[7-[[6-(ethylamino)-3-pyridinyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839707-48-1 HCPLUS
 CN Benzamide, N-[3-[7-[(2,6-dimethyl-4-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-49-2 HCPLUS
 CN Benzamide, N-[3-[7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-50-5 HCPLUS
 CN Benzamide, N-[3-[7-[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 839707-53-8 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 839707-54-9 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839707-55-0 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 839707-56-1 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(1-methyl-1H-pyrazol-5-yl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-57-2 HCAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-58-3 HCAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-59-4 HCAPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-morpholinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-60-7 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-61-8 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-[(diethylamino)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-62-9 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-63-0 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-morpholinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-64-1 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(dimethylamino)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-65-2 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-66-3 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-67-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-morpholinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-68-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-69-6 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-70-9 HCPLUS

CN Benzamide, 4-[(cyclopropylamino)methyl]-N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-71-0 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-72-1 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(1-pyrrolidinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-73-2 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-74-3 HCPLUS

CN Benzamide, 4-[(diethylamino)methyl]-N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-75-4 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-76-5 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(4-ethyl-1-piperazinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-77-6 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-78-7 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-(1-pyrrolidinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-79-8 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-80-1 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-81-2 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-[3-(dimethylamino)-1-pyrrolidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-82-3 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-83-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-84-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-ethyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-85-6 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-[3-(dimethylamino)-1-pyrrolidinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-86-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839707-87-8 HCPLUS

CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-01-9 HCPLUS

CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)amino]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-02-0 HCPLUS


CN Benzamide, N-[3-[(1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)amino]-4-methylphenyl]-3-[(3-[(methylsulfonyl)amino]phenyl)methyl]-4-[(4-(dimethylaminophenyl)methyl)-3-(trifluoromethyl)phenyl]benzamide. (9CI) (CA INDEX NAME)



RN 839708-03-1 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(methylsulfonyl)amino]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me

RN 839708-08-6 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[(4-methyl-2-thiazolyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 839708-09-7P 839708-10-0P 839708-11-1P


839708-13-3P 839708-17-7P 839708-22-4P
 839708-23-5P 839708-24-6P 839708-25-7P
 839708-26-8P 839708-27-9P 839708-28-0P
 839708-29-1P 839708-30-4P 839708-31-5P
 839708-32-6P 839708-33-7P 839708-34-8P
 839708-35-9P 839708-36-0P 839708-37-1P
 839708-38-2P 839708-39-3P 839708-40-6P
 839708-41-7P 839708-42-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidines as protein kinase inhibitors)

RN 839708-09-7 HCPLUS


CN 4-Thiazoleacetic acid, 2-[(5,6,7,8-tetrahydro-8-methyl-6-[2-methyl-5-[(3-(trifluoromethyl)benzoyl]amino]phenyl]-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 839708-10-0 HCPLUS

CN Benzamide, N-[3-[7-[(3-aminophenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839708-11-1 HCPLUS

CN Benzamide, N-[3-[7-(cyclohexylamino)-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839708-13-3 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839708-17-7 HCPLUS

CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1-ethyl-1,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839708-22-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-7-[(3-hydroxyphenyl)amino]-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839708-23-5 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[3-[4-morpholinylsulfonyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-24-6 HCAPLUS


CN Benzamide, N-[3-[7-[3-[[(dimethylamino)methyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-25-7 HCAPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[3-[4-methyl-1-piperazinyl]sulfonyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 --CF_3

RN 839708-26-8 HCPLUS


CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[2-(4-methyl-1-piperazinyl)-4-pyridinyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-27-9 HCPLUS

CN 1-Piperazinecarboxamide, 4-methyl-N-[3-[[5,6,7,8-tetrahydro-8-methyl-6-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 839708-28-0 HCPLUS


CN Benzamide, N-[3-[7-[[[(2R)-1-ethyl-2-pyrrolidinyl]methyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839708-29-1 HCPLUS

CN Benzamide, N-[3-(7-amino-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-30-4 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(4-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-31-5 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(3-pyridinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-32-6 HCPLUS


CN Benzamide, N-[3-[7-[(6-(dimethylamino)-3-pyridinyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-33-7 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-7-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 ---CF_3


RN 839708-34-8 HCPLUS

CN Benzamide, N-[3-[7-[[3-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 839708-35-9 HCPLUS

CN Benzamide, N-[3-[1,4-dihydro-1-methyl-2-oxo-7-(5-pyrimidinylamino)pyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-36-0 HCPLUS

CN Benzamide, 3-[acetyl amino]-N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 839708-37-1 HCPLUS


CN Benzamide, 3-[2-(dimethylamino)ethoxy]-N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 839708-38-2 HCPLUS

CN Benzamide, N-[3-[7-[(3-(dimethylamino)phenyl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-[2-(4-morpholinyl)ethoxy]-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 839708-39-3 HCPLUS

CN Benzamide, 3-[[2-(dimethylamino)ethyl]amino]-N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-40-6 HCPLUS

CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 839708-41-7 HCPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-1-methyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 839708-42-8 HCPLUS

CN Benzamide, N-[3-[7-[[3-(dimethylamino)phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 839708-47-3P 839708-48-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidopyrimidines as protein kinase inhibitors)

RN 839708-47-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-(dimethylamino)phenyl]amino]-3,4-dihydro-1-methyl-3-(2-methyl-5-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 839708-48-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(5-amino-2-methylphenyl)-7-[[3-

(dimethylamino)phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



L27 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:857176 HCAPLUS
 DOCUMENT NUMBER: 141:350187
 TITLE: Preparation of pyrimido compounds having antiproliferative activity
 INVENTOR(S): Chen, Yi; Dermatakis, Apostolos; Liu, Jin-jun; Luk, Kin-chun; Michoud, Christophe; Rossman, Pamela Loreen
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 55 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204427	A1	20041014	US 2004-817697	20040402
WO 2004089955	A1	20041021	WO 2004-EP3447	20040401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-461694P	P 20030410
OTHER SOURCE(S):		MARPAT 141:350187		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Disclosed are methods for preparing novel pyrimido compds. I [R1 = H, (un)substituted-alkyl, -cycloalkyl, -alkynyl, etc.; R2 and R3 independently = H, halo, (un)substituted-alkyl, -alkenyl, etc.; R4-8 independently = H, hydroxyalkyl, alkoxyalkyl, halo, etc.] that are selective inhibitors of both KDR and FGFR kinases. Thus, e.g., II was prep'd via acylation of trans-4-(tert-butyldimethylsilyloxy)cyclohexylami

ne (preparation given) with phosgene and subsequent cyclization with (2,4-dichloropyrimidin-5-ylmethyl)(4-methoxyphenyl)amine followed by desilylation. The IC₅₀ values for I were as follows: KDR less than 0.50 μM; FGFR less than 2 μM. These compds. and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compns. containing these compds. and methods of treating cancer.

IT 774232-16-5P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-1-yl]propionitrile
 774232-32-5P, 4-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]piperidine-1-carboxylic acid tert-butyl ester 774232-33-6P, trans-1-[4-(tert-Butyldimethylsilyloxy)cyclohexyl]-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-34-7P, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]piperidine-1-carboxylic acid tert-butyl ester
 774232-35-8P, cis-1-[3-(tert-Butyldimethylsilyloxy)cyclopentyl]-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-44-9P 774232-45-0P 774232-50-7P
 774232-55-2P 774232-58-5P 774232-60-9P
 774232-61-0P 774232-62-1P 774232-63-2P
 774232-64-3P 774232-68-7P 774232-71-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)


RN 774232-16-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-propanenitrile, 3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)-(9CI) (CA INDEX NAME)



RN 774232-32-5 HCPLUS


CN 1-Piperidinecarboxylic acid, 4-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 774232-33-6 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-34-7 HCPLUS


CN 1-Piperidinecarboxylic acid, 3-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 774232-35-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R,3S)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-44-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-1-[trans-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-45-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-50-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R,3R)-3-[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 774232-55-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S,3S)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 774232-58-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1α,3α,5α)-3,5-bis[[[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-60-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-bis([(1,1-dimethylethyl)diphenylsilyl]oxy)cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-61-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-bis([(1,1-dimethylethyl)diphenylsilyl]oxy)cyclohexyl]-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-62-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-bis[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-63-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-bis[(1,1-dimethylethyl)diphenylsilyl]oxy]cyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-64-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-bis[(1,1-dimethylethyl)diphenylsilyloxy]cyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-68-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[(1,1-dimethylethyl)diphenylsilyloxy]-1-methylethyl]-3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-71-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R,3R)-3-[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclopentyl-3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 774231-91-3P, 1-Cyclohexyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-92-4P,
 3-(4-Methoxyphenyl)-7-phenylamino-1-piperidin-4-yl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-93-5P,
 1-(trans-4-Hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-94-6P,
 3-(4-Methoxyphenyl)-7-phenylamino-1-piperidin-3-yl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-95-7P,
 1-Cyclopentyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-96-8P,
 1-(1,1-Dioxo-tetrahydrothiophen-3-yl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-97-9P,
 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]piperidine-1-carboxaldehyde 774231-98-0P,
 3-(4-Methoxyphenyl)-7-phenylamino-1-(tetrahydro-pyran-4-yl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774231-99-1P,
 1-(trans-3-Hydroxycyclopentyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-00-7P,
 1-(cis-3-Hydroxycyclopentyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 774232-01-8P,

(R) -3- (4-Methoxyphenyl) -7-phenylamino-1-(tetrahydrofuran-3-yl) -3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-02-9P**,
 (R) -3- (4-Methoxyphenyl) -7-phenylamino-1-(pyrrolidin-3-yl) -3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-03-0P**,
 trans-7-(4-Fluorophenylamino)-1-(3-hydroxycyclopentyl)-3-(4-methoxyphenyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-04-1P**,
 trans-3-(2-Fluoro-4-methoxyphenyl)-1-(3-hydroxycyclopentyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-05-2P**,
 (S)-(+)-1-(2-Hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-06-3P**,
 (S)-(+)-7-(4-Fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-07-4P, trans-3-(2-Fluoro-4-methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(4-methoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-08-5P**, trans-3-(2-Fluoro-4-methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(3,4-dimethoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-09-6P**,
 trans-3-(4-Methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(3,4-dimethoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-10-9P, trans-3-(4-Methoxyphenyl)-1-(4-hydroxycyclohexyl)-7-(4-methoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-11-0P, (S)-(+)-3-(2-Fluoro-4-methoxyphenyl)-7-(4-fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-12-1P**, (S)-(+)-3-(2-Fluoro-4-methoxyphenyl)-1-(2-hydroxy-1-methylethyl)-7-(4-methoxyphenylamino)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-13-2P**,
 (R)-(-)-1-(2-Hydroxy-1-methylethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-14-3P**,
 3-(4-Methoxyphenyl)-1-methyl-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one **774232-15-4P**, 1-(2-Methoxyethoxymethyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-17-6P **774232-18-7P**, (R)-1-(2-Hydroxypropyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-19-8P **774232-21-2P**, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-1-yl]propionamide
774232-22-3P, (S)-(+)-1-(2-Hydroxypropyl)-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-23-4P **774232-24-5P** **774232-25-6P**
774232-26-7P **774232-27-8P** **774232-28-9P**
774232-29-0P, (R)-3-(4-Ethylphenyl)-7-(4-fluorophenylamino)-1-(2-hydroxy-1-methylethyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-30-3P, trans-3-(4-Ethylphenyl)-7-(4-fluorophenylamino)-1-(3-hydroxycyclopentyl)-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
774232-31-4P, 1-Cyclopropylmethyl-3-(4-methoxyphenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)


RN 774231-91-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclohexyl-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-(9CI) (CA INDEX NAME)



RN 774231-92-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 774231-93-5 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 774231-94-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 774231-95-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 774231-96-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)




RN 774231-97-9 HCPLUS

CN 1-Piperidinecarboxaldehyde, 3-[3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 774231-98-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 774231-99-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-00-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-01-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-[(3R)-tetrahydro-3-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-02-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-1-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-03-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-04-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-05-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 774232-06-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 774232-07-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-08-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 774232-09-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3,4-dimethoxyphenyl)amino]-3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-10-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 774232-11-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 774232-12-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-7-[(4-methoxyphenyl)amino]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 774232-13-2 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 774232-14-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 774232-15-4 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(2-methoxyethoxy)methyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 774232-17-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 774232-18-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(2R)-2-hydroxypropyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-19-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 774232-21-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-propanamide, 3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 774232-22-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(2S)-2-hydroxypropyl]-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 774232-23-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-24-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-dihydroxycyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-25-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-dihydroxycyclohexyl]-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-26-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-dihydroxycyclohexyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-27-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-(phenylamino)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-28-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1 α ,3 α ,5 α)-3,5-dihydroxycyclohexyl]-3-(2-fluoro-4-methoxyphenyl)-7-[(4-fluoro-3-methoxyphenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 774232-29-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-30-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-ethylphenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3S)-3-hydroxycyclopentyl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 774232-31-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-(cyclopropylmethyl)-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)



IT 774232-74-5P 774232-75-6P 774232-78-9P

774232-79-0P 774232-80-3P 774232-86-9P

774232-90-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)

RN 774232-74-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[[[1,1-dimethylethyl]diphenylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-75-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-methylethyl]-7-[(4-fluorophenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-78-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-7-[(4-fluorophenyl)amino]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-79-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-80-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-86-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(2R)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]propyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774232-90-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(2S)-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]propyl]-3,4-dihydro-3-(4-methoxyphenyl)-7-(phenylamino)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 3 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:412946 HCPLUS

DOCUMENT NUMBER: 140:423694

TITLE: Preparation of pyrimidopyrimidinone derivatives having anticancer activity

INVENTOR(S): Dermatakis, Apostolos; Kabat, Marek Michal; Luk, Kin-Chun; Rossman, Pamela Loreen; So, Sung-Sau

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041822	A1	20040521	WO 2003-EP11896	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110773	A1	20040610	US 2003-689438	20031020
US 2005075272	A1	20050407	US 2003-689235	20031020
PRIORITY APPLN. INFO.:			US 2002-423670P	P 20021104
OTHER SOURCE(S):	MARPAT	140:423694		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = H, (substituted)alkyl, (substituted)aryl, (substituted)heteroaryl, (substituted)heterocycle, (substituted)cycloalkyl, (substituted)alkenyl, (substituted)alkynyl; R2, R3, R4 = H, halo, COR10, CO2R10, CONR10R11, SOR10, SO2R10, CN, or NO2; R5, R6, R7, R8 = H, (substituted)alkyl, (substituted)amino, OH, halo, etc.; R9 = H, -COOCR12R13OCOR14, or COR15; R10, R11 = H, (substituted)alkyl, (substituted)cycloalkyl, (substituted)heterocycle, etc.; R12, R13 = H, alkyl; R14 = (substituted)alkyl; R15 = H, alkyl or cycloamines with 3-7 atoms] were prepared as anti-proliferative agents for the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. For example, reaction of 7-chloro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-3,4-dihydro-1H-pyrimido[4,5-d]-2-one (preparation given) with aniline yielded compound II. The latter showed inhibition of KDR, FGFR, EGFR and PDGFR with IC50 < 10 µM.

IT 690991-80-1P 690991-82-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidinone derivs. having anticancer activity)

RN 690991-80-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690991-82-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 690991-78-7P 690991-94-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidopyrimidinone derivs. having anticancer activity)


RN 690991-78-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 690991-94-7 HCPLUS

CN Benzonitrile, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




IT 690991-84-5P 690991-86-7P 690991-88-9P
 690991-90-3P 690991-92-5P 690991-96-9P
 690991-98-1P 690992-00-8P 690992-02-0P
 690992-04-2P 690992-06-4P 690992-12-2P
 690992-16-6P 690992-17-7P 690992-19-9P
 690992-21-3P 690992-23-5P 690992-25-7P
 690992-27-9P 690992-29-1P 690992-30-4P
 690992-32-6P 690992-34-8P 690992-36-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidinone derivs. having anticancer activity)


RN 690991-84-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1,3-bis(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-86-7 HCPLUS

CN Benzonitrile, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 690991-88-9 HCPLUS

CN Benzamide, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 690991-90-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 4-ethyl-3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-92-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 690991-96-9 HCPLUS

CN Benzamide, 3-[3-(2-fluoro-4-methoxyphenyl)-3,4-dihydro-4-methyl-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 690991-98-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-(1-methylethyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 690992-00-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-5-methoxyphenyl)-3,4-dihydro-4-methyl-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 690992-02-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-04-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 690992-06-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 690992-12-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-1-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-16-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-(trans-4-hydroxycyclohexyl)-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 690992-17-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-19-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1S,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-21-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-23-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1S,3S)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-25-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-3-(4-methoxyphenyl)-4-methyl-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-27-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chlorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-29-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chloro-2-fluorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-30-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chlorophenyl)-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-32-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chloro-2-fluorophenyl)-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-34-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chlorophenyl)-3,4-dihydro-1-[(2S)-3-hydroxy-2-methylpropyl]-4-methyl-7-(phenylamino)-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 690992-36-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chloro-2-fluorophenyl)-3,4-

dihydro-1-[(2S)-3-hydroxy-2-methylpropyl]-4-methyl-7-(phenylamino)-, (4S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 690992-65-5P 690992-70-2P 690992-72-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidopyrimidinone derivs. having anticancer activity)

RN 690992-65-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1S)-2-[[{(1,1-dimethylethyl)diphenylsilyl}oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-70-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[[{(1,1-dimethylethyl)diphenylsilyl}oxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690992-72-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[(1R)-2-[(1,1-dimethylethyl)diphenylsilyloxy]-1-methylethyl]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-(phenylamino)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 4 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:412945 HCPLUS

DOCUMENT NUMBER: 140:423693

TITLE: Preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer

INVENTOR(S): Luk, Kin-Chun; Rossman, Pamela Loreen; Scheiblich, Stefan; So, Sung-Sau

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2004041821	A1	20040521	WO 2003-EP311892	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004110773	A1	20040610	US 2003-689438	20031020
US 2005075272	A1	20050407	US 2003-689235	20031020
PRIORITY APPLN. INFO.:			US 2002-423670P	P 20021104

OTHER SOURCE(S) : MARPAT 140:423693

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB MovPyrimido compds. I (R1 = H, alkyl, substituted alkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkenyl, alkynyl; R2,R3,R4 independently = H, amine, alkoxy, sulfanyl, alkyl, cycloalkyl, alkenyl, alkynyl; R5, R6, R7, R8 independently = H, lower alkyl, amine, OH, alkoxy, sulfanyl, halogen, ketone, ester, amide, sulfonyl, CN; R9 = H, diester, ketone), that are selective inhibitors of the Src family of tyrosine kinases are prepared for the treatment of breast, colon, pancreatic, and hepatic cancers. Thus, 1-(2,4-dichloro-pyrimidin-5-yl)-ethanol was treated with phosphorus oxybromide and diisopropyl amine to give 2,4-dichloro-5-(1-bromoethyl)-pyrimidine which was treated with p-anisidine, potassium carbonate, and potassium iodide to give the corresponding amine. The above amine was reacted with 3-cyanophenyl isocyanate in toluene to give II. II was reacted with acetic acid 2-(3-amino-phenyl)-Et ester, followed by treatment with potassium carbonate in methanol to give III. III showed and IC50 of less than 1.0 μ M against Src tyrosine kinase. Also disclosed are pharmaceutical compns. containing these compds. and the use for treating cancer.


IT 690995-25-6P 690995-29-0P 690995-31-4P

690995-33-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)

RN 690995-25-6 HCPLUS


CN Benzonitrile, 3-[7-[(3-[2-(dimethylamino)ethyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl] - (9CI) (CA INDEX NAME)




RN 690995-29-0 HCPLUS
 CN Benzonitrile, 3-[3,4-dihydro-7-[[3-[2-hydroxyethyl]phenyl]amino]-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
 (CA INDEX NAME)



RN 690995-31-4 HCPLUS
 CN Benzonitrile, 3-[7-[[3-[2-(diethylamino)ethyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI)
 (CA INDEX NAME)



RN 690995-33-6 HCPLUS
 CN Benzonitrile, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-[[3-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




IT 690995-35-8P 690995-36-9P 690995-37-0P
690995-38-1P 690995-39-2P 690995-40-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)


RN 690995-35-8 HCPLUS

CN Benzamide, 3-[7-[(3-[(2-(diethylamino)ethyl]phenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)




RN 690995-36-9 HCPLUS

CN Benzamide, 3-[7-[(3-[(2-(dimethylamino)ethyl]phenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 690995-37-0 HCPLUS


CN Benzamide, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-[[3-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



RN 690995-38-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1,4-dimethyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 690995-39-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1,4-dimethyl- (9CI) (CA


(INDEX NAME)



RN 690995-40-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



IT 690995-23-4P 690995-24-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)

RN 690995-23-4 HCPLUS

CN Benzonitrile, 3-[7-[(3-[2-(acetyloxy)ethyl]phenyl)amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl] - (9CI)
(CA INDEX NAME)

RN 690995-24-5 HCPLUS

CN Benzonitrile, 3-[3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-7-[[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-(9CI) (CA INDEX NAME)



L27 ANSWER 5 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:372873 HCPLUS

DOCUMENT NUMBER: 140:391294

TITLE: Preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives as inhibitors of src family tyrosine kinases

INVENTOR(S): Cai, Jianping; Dimoudis, Nikolaos; Honold, Konrad; Luk, Kin-Chun; Scheiblich, Stefan; Sudergat, Hilke; Tiefenthaler, Georg; Tonn, Oliver

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 31 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087600	A1	20040506	US 2003-697543	20031030
WO 2004041823	A1	20040521	WO 2003-EP12203	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2002-24573 A 20021104

OTHER SOURCE(S): CASREACT 140:391294; MARPAT 140:391294

GI



AB The title compds. [I; R1 = H, alkyl, aryl, etc.; R2 = halo, CN, CF₃; R3 = halo, OH, CN, etc.; n = 0-2; R4 = H, alkyl, alkoxy, CN; A = (un)substituted 2,3-dihydrobenzo[1,4]dioxin-6-yl, benzodioxane-6-yl, 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-7-yl, etc.] which are protein kinase inhibitors, in particular they inhibit the src family tyrosine kinases, and therefore useful for the treatment of diseases mediated by src tyrosine kinases, including cell proliferative disorders such as cancer, were prepared. Thus, reacting 3-(2-bromophenyl)-3,4-dihydro-7-methanesulfonyl-1-methylpyrimido[4,5-d]pyrimidin-2(1H)-one with 2-hydroxymethyl-6-amino-1,4-benzodioxane (preparation given) afforded 3-(2-bromophenyl)-7-(2-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-ylamino)-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2(1H)-one which showed IC₅₀ of 7.5 nM against src kinase, and IC₅₀ of 6.3 nM against lck kinase. The pharmaceutical composition containing the compound I is claimed.


IT 686756-87-6P 686756-91-2P 686756-98-9P

686757-21-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)


RN 686756-87-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686756-91-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2-(chloromethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686756-98-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-2-[(4-methylphenyl)sulfonyl]oxy]methyl]-1,4-benzodioxin-6-ylamino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-21-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



IT 686756-95-6P 686757-02-8P 686757-06-2P

686757-10-8P 686757-14-2P 686757-17-5P

686757-25-5P 686757-29-9P 686757-33-5P

686757-37-9P 686757-40-4P 686757-44-8P

686757-48-2P 686757-55-1P 686757-60-8P

686757-65-3P 686757-70-0P 686757-73-3P

686757-78-8P 686757-82-4P 686757-88-0P

686757-93-7P 686759-58-0P 686759-62-6P

686759-66-0P 686759-70-6P 686759-74-0P

686759-78-4P 686759-82-0P 686759-86-4P

686759-92-2P 686759-99-9P 686760-03-2P

686760-07-6P 686760-11-2P 686760-14-5P

686760-18-9P 686760-22-5P 686760-26-9P


686760-30-5P 686760-34-9P 686760-37-2P
 686760-41-8P 686760-47-4P 686760-51-0P
 686760-55-4P 686760-59-8P 686760-63-4P
 686760-67-8P 686760-70-3P 686760-74-7P
 686760-78-1P 686760-82-7P 686760-92-9P
 686760-96-3P 686761-00-2P 686761-07-9P
 686761-11-5P 686761-18-2P 686761-21-7P
 686761-25-1P 686761-29-5P 686761-36-4P
 686766-23-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)


RN 686756-95-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-2-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI)
 (CA INDEX NAME)




RN 686757-02-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-06-2 HCPLUS

CN Spiro[1,3-benzodioxole-2,4'-piperidine], 1'-acetyl-5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 686757-10-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-methyl-7-(spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino)- (9CI) (CA INDEX NAME)



RN 686757-14-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-17-5 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686757-25-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-[(3-methoxy-4-methyl-1-oxido-4H-1,4-benzothiazin-7-yl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-29-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-33-5 HCPLUS


CN 1H-Isoindole-1,3(2H)-dione, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-(2-hydroxy-1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 686757-37-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-1-methyl-7-(spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino)- (9CI) (CA INDEX NAME)



RN 686757-40-4 HCPLUS


CN 1H-Isoindole-1,3(2H)-dione, 5-[(6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 686757-44-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,3-dioxido-1,3-benzoxathiol-5-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-48-2 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1,3-benzodioxol-5-ylamino)-3-(2-bromophenyl)-3,4-dihydro-1-methyl]- (9CI) (CA INDEX NAME)



RN 686757-55-1 HCPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 686757-60-8 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686757-65-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-5-methoxyphenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-70-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-3-(2-fluoro-6-methoxyphenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686757-73-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686757-78-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686757-82-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686757-88-0 HCPLUS

CN Benzonitrile, 2-[7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 686757-93-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-2-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-58-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-(1,3-benzodioxol-5-ylamino)-3-(2,4-dichlorophenyl)-3,4-dihydro-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 686759-62-6 HCPLUS

CN Benzonitrile, 2-[7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]- (9CI) (CA INDEX NAME)




RN 686759-66-0 HCPLUS

CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxylic acid, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 686759-70-6 HCPLUS

CN Spiro[1,3-benzodioxole-2,4'-piperidine], 1'-acetyl-5-[(6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 686759-74-0 HCPLUS

CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxylic acid, 5-[(6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 686759-78-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(1'-ethylspiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-82-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-[(1'-(2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-86-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-7-[(1'-(2-methoxyethyl)spiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 686759-92-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-methyl-7-[(1'-methylspiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 686759-99-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-3,4-dihydro-1-methyl-7-[(1'-methylspiro[1,3-benzodioxole-2,4'-piperidin]-5-yl)amino]-(9CI) (CA INDEX NAME)




RN 686760-03-2 HCAPLUS

CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-acetonitrile, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-(9CI) (CA INDEX NAME)




RN 686760-07-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-5-methoxyphenyl)-3,4-dihydro-1-methyl-7-(spiro[1,3-benzodioxole-2,4'-piperidin]-5-ylamino)-(9CI) (CA INDEX NAME)




RN 686760-11-2 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl-(9CI) (CA INDEX NAME)




RN 686760-14-5 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-3-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686760-18-9 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl group. - (9CI) (CA INDEX NAME)




RN 686760-22-5 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3-(dimethylamino)methyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-26-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3-[(dimethylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-30-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2-[(cyclopropylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-34-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-3-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-37-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[[2,3-dihydro-3-(4-morpholinylmethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-41-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-3-(1-pyrrolidinylmethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-47-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-51-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-55-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-59-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-1,4-benzoxathiin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-63-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-67-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-70-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-74-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-78-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1-oxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-82-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-92-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686760-96-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-00-2 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 686761-07-9 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-11-5 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-1,1-dioxido-3-oxo-2H-1,4-benzothiazin-7-yl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 686761-18-2 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 686761-21-7 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 5-[[6-(2-bromophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 686761-25-1 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 686761-29-5 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 5-[[6-(2-bromo-6-fluorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-2-(2-hydroxy-1,1-dimethylethyl)-(9CI) (CA INDEX NAME)




RN 686761-36-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromo-6-fluorophenyl)-7-[(3,3-dioxido-1,3-benzoxathiol-5-yl)amino]-3,4-dihydro-1-methyl-(9CI) (CA INDEX NAME)




RN 686766-23-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazin-6-yl)amino]-3,4-dihydro-1-methyl-(9CI) (CA INDEX NAME)



L27 ANSWER 6 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:162462 HCPLUS
 DOCUMENT NUMBER: 140:199340
 TITLE: Preparation of pyrimidopyrimidinone derivatives having antiproliferative activity
 INVENTOR(S): Chen, Yi; Daniewski, Andrzej Robert; Harris, William;
 Kabat, Marek Michal; Liu, Emily Aijun; Liu, Jin-jun;
 Luk, Kin-chun; Michoud, Christophe
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 25 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004038995	A1	20040226	US 2003-623972	20030721
WO 2004018472	A2	20040304	WO 2003-EP8744	20030807
WO 2004018472	A3	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-403519P	P 20020814
OTHER SOURCE(S):	MARPAT 140:199340			
GI				



AB The title I [R1 = H, COR4, COOCHR5OCOR4; R2,R3 = H or OR5; R4 = alkyl, or alkyl substituted by NR5R6, SR5, OR5, (substituted)aryl, heteroaryl, heterocycle; R5, R6 = H, alkyl or NR5R6 form a ring optionally including one or more addnl. N or O] were prepared as selective inhibitors of both KDR


and FGFR kinases and are selective against LCK. Thus, reaction of 7-chloro-3-(4-methoxyphenyl)-1-phenyl-1,3,4-trihydropyrimidino[4,5-d]-2-one (preparation given) with aniline yielded compound II (R1, R2, R3 = H). The latter showed inhibition of KDR, FGFR, EGFR and PDGFR with IC₅₀ = 0.044, 0.076, 0.360, and 0.130 μM, resp.

IT 663198-02-5P 663198-20-7P 663198-33-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidopyrimidinone derivs. having antiproliferative activity)


RN 663198-02-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 663198-20-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)amino]-1-phenyl- (9CI) (CA INDEX NAME)



RN 663198-33-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)




IT 663198-18-3P 663198-22-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidopyrimidinone derivs. having antiproliferative activity)

RN 663198-18-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(4-hydroxyphenyl)amino]-3-(4-methoxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)




RN 663198-22-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)-, mono(methanesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 663198-02-5


CMF C25 H21 N5 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



L27 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:80385 HCAPLUS

DOCUMENT NUMBER: 140:146153

TITLE: Preparation of pyrimidopyrimidinones as kinase inhibitors

INVENTOR(S): Chivikas, Connolly Cleo J.; Deur, Christopher James; Hamby, James Marino; Hoyer, Denton Wade; Limberakis, Chris; Reed, Jessica Elizabeth; Schroeder, Mel Conrad; Taylor, Clarke

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 44 pp.

CODEN: USXXCO



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004019210	A1	20040129	US 2003-621983	20030717
CA 2493633	AA	20040205	CA 2003-2493633	20030721
WO 2004011465	A1	20040205	WO 2003-IB3359	20030721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-398638P	P 20020725
			WO 2003-IB3359	W 20030721

OTHER SOURCE(S) : MARPAT 140:146153
GI

AB This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimidopyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula I [A = O, NH₂, mono(or di)alkylamino, NHCONHR₁₂ (wherein R₁₂ = alkyl, alkylene cycloalkyl); B, C, D = CH, N (with the proviso that C and D are not both N); R₁ = alkyl]

(optionally substituted by CO₂H), (un)substituted Ph, CH₂Ph, piperidinyl, etc.; R₂ = H, Cl, F; R₃ = H, Cl, F (at least one of R₂ or R₃ = F); R₄ = H, OH, OMe, OEt (if R₄ = H, R₂ and R₃ is not H); R₅ = OMe, OEt; R₆ = H, alkyl-NH₂, O-alkyl-NH₂, etc.) that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediates for their synthesis, as well as pharmaceutical compns. and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer (no biol. data given). Synthesis of 35 title compds. I is described.

E.g., a multi-step synthesis of II was given.


IT 651734-15-5P 651734-16-6P 651734-35-9P

651734-43-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidopyrimidinones as kinase inhibitors)

RN 651734-15-5 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[{4-(diethylamino)butyl}amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-16-6 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[[(4S,5S)-5-(hydroxymethyl)-2-phenyl-1,3-dioxolan-4-yl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651734-35-9 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 651734-43-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 651734-14-4P 651734-17-7P 651734-18-8P

651734-19-9P 651734-20-2P 651734-21-3P

651734-22-4P 651734-23-5P 651734-24-6P

651734-25-7P 651734-26-8P 651734-27-9P

651734-28-0P 651734-29-1P 651734-30-4P

651734-31-5P 651734-32-6P 651734-33-7P

651734-34-8P 651734-36-0P 651734-38-2P

651734-39-3P 651734-40-6P 651734-41-7P

651734-42-8P 651734-45-1P 651734-46-2P

651734-47-3P 651734-48-4P 651734-49-5P


651734-50-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidopyrimidinones as kinase inhibitors)

RN 651734-14-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[{4-(diethylamino)butyl}amino]-3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-17-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2S,3S)-2,3,4-trihydroxybutyl]amino- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-18-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 651734-19-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 651734-20-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2-hydroxypropyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-21-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2-(2-hydroxyethoxy)ethyl]amino]- (9CI)

(CA INDEX NAME)




RN 651734-22-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopropyl-7-[{4-(diethylamino)butyl}amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 651734-23-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{4-(diethylamino)butyl}amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-24-6 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[{2-hydroxy-1-(hydroxymethyl)ethyl}amino]- (9CI) (CA INDEX NAME)



RN 651734-25-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 651734-26-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R,3R)-2,3-dihydroxybutyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-27-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R)-2,3-dihydroxypropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-28-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-amino-2,3-dihydroxybutyl)amino]-1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-29-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(2S,3S)-2,3,4-trihydroxybutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-30-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(2R,3S)-4-amino-2,3-dihydroxybutyl]amino- (9CI) (CA INDEX NAME)



RN 651734-31-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2S,3S)-4-amino-2,3-dihydroxybutyl]amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651734-32-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-[(2S,3S)-4-


hydroxyethyl)amino]propyl]amino]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-33-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2S)-2,3-dihydroxypropyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 651734-34-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R,3R)-2,3-dihydroxybutyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-36-0 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl] - (9CI)
(CA INDEX NAME)


RN 651734-38-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-1-(4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 651734-37-1


CMF C19 H22 F2 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 651734-39-3 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[2-hydroxy-1-(hydroxymethyl)ethyl]amino] - (9CI) (CA INDEX NAME)




RN 651734-40-6 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(4-hydroxybutyl)amino] - (9CI) (CA INDEX NAME)



RN 651734-41-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[(2S)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 651734-42-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 651734-45-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(methylamino)-1-(4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 651734-44-0


CMF C20 H24 F2 N6 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 651734-46-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-[(2R)-2,3-dihydroxypropyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-47-3 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[[4-(diethylamino)butyl]amino]-3-(3-ethoxy-2,6-difluorophenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 651734-48-4 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-7-[[(2R)-2,3-dihydroxypropyl]amino]-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651734-49-5 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-ethyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 651734-50-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2-fluoro-3,5-dimethoxyphenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 651735-18-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidopyrimidinones as kinase inhibitors)


RN 651735-18-1 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[7-amino-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L27 ANSWER 8 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2003:651919 HCPLUS
 DOCUMENT NUMBER: 140:16695
 TITLE: Solid-phase synthesis of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones
 AUTHOR(S): Gravaleau, Nadege; Masquelin, Thierry
 CORPORATE SOURCE: Combinatorial & Parallel Chemistry, Basilea Pharmaceutica Ltd., Basel, 4002, Switz.
 SOURCE: Synthesis (2003), (11), 1739-1743
 CODEN: SYNTBF; ISSN: 0039-7881
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:16695
 AB The authors report a novel and versatile solid-phase synthesis of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones starting from the polymer-bound Et 4-amino-2-sulfanylpyrimidine-5-carboxylate. The key step is based on the reaction of the support-bound pyrimidine with isocyanates, involving formation of a carbamate intermediate, followed by a base-catalyzed intramol. ring closure, to give polymer-bound 3-monosubstituted 1H-pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones. At this stage, subsequent treatment with alkyl halides led to 1,3-disubstituted 2H-pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione intermediates, which after oxidation and cleavage with various amines gave 1,3-disubstituted 7-amino-2H-pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones in moderate yields and high purity.
 IT 630394-21-7P 630394-23-9P 630394-24-0P
 630394-25-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones)
 RN 630394-21-7 HCPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1-(cyclopropylmethyl)-3-(2-fluorophenyl)-7-[[3-(4-morpholinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 630394-23-9 HCAPLUS
 CN Benzoic acid, 3-[1-(3-cyanopropyl)-1,4-dihydro-7-[[3-(4-morpholinyl)propyl]amino]-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 630394-24-0 HCAPLUS
 CN Benzoic acid, 3-[1-[(3-fluorophenyl)methyl]-1,4-dihydro-7-[[3-(4-morpholinyl)propyl]amino]-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 630394-25-1 HCAPLUS
 CN Benzoic acid, 3-[1-[(4-cyanophenyl)methyl]-1,4-dihydro-7-[[3-(4-morpholinyl)propyl]amino]-2,4-dioxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STM

ACCESSION NUMBER: 2001:300721 HCAPLUS

DOCUMENT NUMBER: 134:326540

TITLE: Preparation of alkylamino substituted bicyclic nitrogen heterocycles for pharmaceutical use as inhibitors of p38 protein kinase

INVENTOR(S): Dunn, James Patrick; Fisher, Lawrence Emerson; Goldstein, David Michael; Harris, William; Hill, Christopher Huw; Smith, Ian Edward David; Welch, Teresa Rosanne

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.

SOURCE: PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029042	A1	20010426	WO 2000-EP10088	20001013
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2388142	AA	20010426	CA 2000-2388142	20001013
BR 2000015243	A	20020716	BR 2000-15243	20001013
EP 1228070	A1	20020807	EP 2000-967864	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200201057	T2	20020923	TR 2002-200201057	20001013
JP 2003512378	T2	20030402	JP 2001-531840	20001013
NZ 518119	A	20040227	NZ 2000-518119	20001013

AU 776250	B2	20040902	AU 2000-77873	20001013
US 6451804	B1	20020917	US 2000-693337	20001020
ZA 2002002540	A	20030630	ZA 2002-2540	20020328
NO 2002001781	A	20020418	NO 2002-1781	20020416
PRIORITY APPLN. INFO. :			US 1999-160803P	P 19991021
			US 2000-213743P	P 20000622
			WO 2000-EP10088	W 20001013

OTHER SOURCE(S) : MARPAT 134:326540
GI



AB Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivs., such as I [R1 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.; R2 = vinyl, alkyl, halogen, heteroalkyl; R3 = alkyl, heteroalkyl, cycloalkyl, heterocyclyl, etc.; R4 = H, alkyl, etc.; n = 0-3], were prepared for pharmaceutical use. The compds. are p38 inhibitors and may be used in the treatment of arthritis, Crohn's disease, irritable bowel syndrome, adult respiratory distress syndrome, chronic obstructive pulmonary disease, osteoporosis, or Alzheimer's disease. Thus, dihydropyrimido[4,5-d]pyrimidinone II (R = NH₂CH₂OH, R3 = Me) was prepared via a substitution reaction of H₂NCH₂CH₂OH with sulfone II (R = SO₂Me, R3 = Me) when combined and heated to 100-110° for 1 h. The prepared dihydropyrimido[4,5-d]pyrimidinone derivs. showed 50% p38 inhibitory activity at concns. < 10 μM.


IT 335651-19-9P 335651-20-2P 335651-24-6P
 335651-30-4P 335651-49-5P 335651-50-8P
 335651-53-1P 335651-55-3P 335651-56-4P
 335651-57-5P 335651-58-6P 335651-61-1P
 335651-77-9P 335651-88-2P 335651-89-3P
 335651-93-9P 335651-94-0P 335651-95-1P
 335651-96-2P 335651-97-3P 335651-98-4P
 335651-99-5P 335652-00-1P 335652-06-7P
 335652-11-4P 335652-12-5P 335652-13-6P
 335652-14-7P 335652-16-9P 335652-18-1P
 335652-22-7P 335652-24-9P 335652-26-1P
 335652-30-7P 335652-32-9P 335652-36-3P
 335652-39-6P 335652-40-9P 335652-41-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)


RN 335651-19-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-methylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-20-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxypropyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-24-6 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-30-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-49-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-methylphenyl)-7-(4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 335651-50-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-methylphenyl)-7-[{1-(phenylmethyl)-4-piperidinyl}amino]- (9CI) (CA INDEX NAME)



RN 335651-53-1 HCAPLUS


CN 4-Piperidinamine, 1-(methylsulfonyl)-N-[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 335651-55-3 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[{1-[(2R)-2,3-dihydroxypropyl]-4-piperidinyl}amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-56-4 HCPLUS

CN 1-Piperidinepropanenitrile, 4-[(5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 335651-57-5 HCPLUS

CN 1-Piperidineacetonitrile, 4-[(5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 335651-58-6 HCPLUS

CN 1-Piperidineacetonitrile, 4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 335651-61-1 HCAPLUS

CN 1-Piperidinepropanoic acid, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, methyl ester
(9CI) (CA INDEX NAME)

RN 335651-77-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry..



RN 335651-88-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-ethoxy-1-(ethoxymethyl)ethyl]-3,4-dihydro-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-89-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-

[[(1S)-2-hydroxy-1-methylethyl]amino]-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-93-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-94-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2-diethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335651-95-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-96-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-97-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-98-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[3-(dimethylamino)-2,2-dimethylpropyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-99-5 HCPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-00-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335652-06-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-11-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-methoxycyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-12-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-(2-methoxyethoxy)cyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-13-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[trans-4-(acetoxy)cyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-14-7 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(trans-4-(2-propenoxy)cyclohexyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-16-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)cyclohexyl]amino-1-methyl- (9CI) (CA INDEX NAME)



RN 335652-18-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-[(2S)-2,3-dihydroxypropoxy]cyclohexyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335652-22-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(4-oxocyclohexyl)amino]- (9CI) (CA INDEX NAME)



RN 335652-24-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(3-hydroxymethyl)-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335652-26-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-30-7 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(4-hydroxyimino)cyclohexyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335652-32-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-36-3 HCPLUS


CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 8-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)



RN 335652-39-6 HCPLUS

CN Methanesulfonamide, N-[trans-4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-40-9 HCPLUS

CN Sulfamide, N'-(trans-4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]cyclohexyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-41-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 335651-18-8P 335651-21-3P 335651-22-4P
 335651-23-5P 335651-25-7P 335651-26-8P
 335651-27-9P 335651-28-0P 335651-29-1P
 335651-31-5P 335651-32-6P 335651-33-7P
 335651-34-8P 335651-36-0P 335651-37-1P
 335651-38-2P 335651-39-3P 335651-40-6P
 335651-41-7P 335651-42-8P 335651-43-9P
 335651-44-0P 335651-45-1P 335651-46-2P
 335651-47-3P 335651-48-4P 335651-52-0P
 335651-54-2P 335651-70-2P 335651-71-3P
 335651-72-4P 335651-73-5P 335651-74-6P
 335651-75-7P 335651-76-8P 335651-78-0P
 335651-79-1P 335651-80-4P 335651-81-5P
 335651-82-6P 335651-83-7P 335651-84-8P
 335651-85-9P 335651-86-0P 335651-87-1P
 335651-90-6P 335651-91-7P 335651-92-8P
 335652-02-3P 335652-04-5P 335652-08-9P
 335652-20-5P 335652-28-3P 335652-34-1P
 335652-37-4P 335652-38-5P 335652-42-1P
 335652-71-6P 335652-72-7P 335652-73-8P
 335652-74-9P 335652-75-0P 335652-76-1P
 335652-77-2P 335652-78-3P 335652-79-4P
 335652-80-7P 335652-81-8P 335652-82-9P
 335652-83-0P 335652-84-1P 335652-85-2P
 335652-86-3P 335652-87-4P 335652-88-5P
 335652-90-9P 335652-91-0P 335652-92-1P
 335652-93-2P 335652-94-3P 335652-95-4P
 335652-96-5P 335652-98-7P 335652-99-8P

335653-00-4P 335653-01-5P 335653-02-6P
 335653-03-7P 335653-04-8P 335653-05-9P
 335653-22-0P 335653-23-1P 335653-24-2P
 335653-37-7P 335653-38-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)

RN 335651-18-8 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxyethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-21-3 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-2-hydroxy-1-methylethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335651-22-4 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-(hydroxymethyl)ethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-23-5 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-

dihydroxypropyl)amino] -3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-25-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxyethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-26-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(3-hydroxybutyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-27-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxybutyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-28-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-29-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-31-5 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-32-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)-2-methylpropyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-33-7 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)butyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-34-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335651-36-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)pentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-37-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-38-2 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335651-39-3 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)cyclopentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-40-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-41-7 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335651-42-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(2-(1-piperidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 335651-43-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(3-(1-piperidinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 335651-44-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(2-(4-morpholinyl)ethyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-45-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(3-(4-morpholinyl)propyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-46-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(tetrahydro-1,1-dioxido-3-thienyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-47-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(2-(2-oxo-1-imidazolidinyl)ethyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-48-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(3-(2-oxo-1-pyrrolidinyl)propyl)amino]- (9CI) (CA INDEX NAME)




RN 335651-52-0 HCPLUS

CN 1-Piperidineacetamide, 4-[(5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 335651-54-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1-(2-hydroxyethyl)-4-piperidinyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-70-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2,2-dimethylpropyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-71-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2,2-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-72-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2-(dimethylamino)ethyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-73-5 HCPLUS

CN Acetamide, N-[2-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 335651-74-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-75-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)pentyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-76-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(3-amino-2-hydroxypropyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-78-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 335651-79-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 335651-80-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-81-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335651-82-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-chlorophenyl)-3,4-dihydro-7-[(1-hydroxymethyl)-2-methylpropyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 335651-83-7 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1-hydroxymethyl)-2-methylpropyl]amino]-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335651-84-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-85-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1R,2S)-2-hydroxycyclohexyl]amino]-1-methyl-3-(2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-86-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-fluorophenyl)-3,4-dihydro-7-[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-87-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(1R,2R)-2-hydroxycyclohexyl]amino]-1-methyl-3-(2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335651-90-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-91-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[(1S,2S)-2-aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335651-92-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[(1R,2R)-2-aminocyclohexyl]amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335652-02-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335652-04-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-3-piperidinyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-08-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-20-5 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-(1,4-dioxaspiro[4.5]dec-8-ylamino)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 335652-28-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo-, methyl ester (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 335652-34-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-37-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetonitrile, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-2-oxo- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-38-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335652-42-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 335652-71-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1,1-dimethylethyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-72-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 335652-73-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxy-1-methylethyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-74-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(2-hydroxypropyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-75-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-76-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[[1-(hydroxymethyl)cyclohexyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-77-2 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[{3-(hydroxymethyl)-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl}amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-78-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[(4-oxocyclohexyl)amino] -, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-79-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[{4-(hydroxyimino)cyclohexyl}amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-80-7 HCPLUS

CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 8-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-81-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-methyl-7-[[trans-4-(2-propenyloxy)cyclohexyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-82-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-methoxycyclohexyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-83-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-(2-methoxyethoxy)cyclohexyl)amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-84-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-(acetoxy)cyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-85-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[trans-4-[(2S)-2,3-dihydroxypropoxy]cyclohexyl]amino]-3,4-dihydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 335652-86-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 335652-87-4 HCPLUS

CN Methanesulfonamide, N-[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-88-5 HCPLUS

CN Sulfamide, N'-[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335652-90-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 335652-91-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(2,3-dihydroxy-1,1-dimethylpropyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-92-1 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-methyl-3-(2-methylphenyl)-7-[(1-(phenylmethyl)-4-piperidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 335652-93-2 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(1-[(2R)-2,3-dihydroxypropyl]-4-piperidinyl)amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 335652-94-3 HCPLUS
 CN 1-Piperidinopropanenitrile, 4-[[5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-95-4 HCPLUS


CN 1-Piperidineacetonitrile, 4-[(5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335652-96-5 HCPLUS

CN 1-Piperidinepropanoic acid, 4-[(5,6,7,8-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335652-98-7 HCPLUS

CN 4-Piperidinamine, 1-(methylsulfonyl)-N-[(5,6,7,8-tetrahydro-8-methyl-6-(2-


methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 335652-99-8 HCPLUS

CN 1-Piperidineacetonitrile, 4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 335653-00-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-01-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-02-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-03-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-
[[[(1S)-2-hydroxy-1-methylethyl]amino]-1-(4-piperidinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 335653-04-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[2-ethoxy-1-
(ethoxymethyl)ethyl]-3,4-dihydro-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 335653-05-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetamide, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-N,N-dimethyl-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-22-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-[2-(methylthio)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-23-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[3-(dimethylamino)-2,2-dimethylpropyl]-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-24-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-37-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 335653-38-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(trans-4-hydroxycyclohexyl)amino]-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

IT 335653-41-3P 335653-74-2P 335653-77-5P
335653-78-6P 335653-79-7P 335653-80-0P
335653-84-4P 335653-85-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)

RN 335653-41-3 HCPLUS


CN 1-Piperidinecarboxylic acid, 4-[[1,5,6,7-tetrahydro-8-methyl-6-(2-methylphenyl)-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 335653-74-2 HCPLUS

CN Sulfamide, N'-[trans-4-[[6-(2-chlorophenyl)-5,6,7,8-tetrahydro-7-oxo-8-[[2-(trimethylsilyl)ethoxy]methyl]pyrimido[4,5-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-77-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-78-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetonitrile, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro-2-oxo-, (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-79-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-7-[(trans-4-[(1,1-dimethylethyl)dimethylsilyl]oxy)cyclohexyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-80-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[trans-4-[(1,1-dimethylethyl)dimethylsilyloxy]cyclohexyl]amino]-3,4-dihydro-1-[2-[(tris(1-methylethyl)silyloxy)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-84-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(trans-4-aminocyclohexyl)amino]-3-(2-chlorophenyl)-3,4-dihydro-1-[(2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 335653-85-5 HCPLUS

CN Methanesulfonamide, N-[trans-4-[(6-(2-chlorophenyl)-5,6,7,8-tetrahydro-7-oxo-8-[(2-(trimethylsilyl)ethoxy)methyl]pyrimido[4,5-d]pyrimidin-2-yl]amino)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:300720 HCAPLUS

DOCUMENT NUMBER: 134:311223

TITLE: Preparation of alkylamino substituted bicyclic nitrogen heterocycles for pharmaceutical use as inhibitors of p38 protein kinase

INVENTOR(S): Dunn, James Patrick; Goldstein, David Michael; Harris, William; Smith, Ian Edward David; Welch, Teresa Rosanne

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029041	A1	20010426	WO 2000-EP10077	20001013
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2388140	AA	20010426	CA 2000-2388140	20001013
BR 2000014973	A	20020716	BR 2000-14973	20001013
TR 200201058	T2	20020722	TR 2002-200201058	20001013
EP 1226144	A1	20020731	EP 2000-972755	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003512377	T2	20030402	JP 2001-531839	20001013
AU 776695	B2	20040916	AU 2001-11375	20001013
US 6642241	B1	20031104	US 2000-693364	20001020
ZA 2002002603	A	20030703	ZA 2002-2603	20020403
NO 2002001783	A	20020416	NO 2002-1783	20020416
PRIORITY APPLN. INFO.:			US 1999-160804P	P 19991021
			US 2000-213718P	P 20000622

OTHER SOURCE(S) :
GI

MARPAT 134:311223

WO 2000-EP10077

W 20001013



AB Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivs., such as I [R1 = H, alkyl, alkenyl, alkynyl, acyl, cycloalkyl, etc.; R2 = vinyl, alkyl, halogen, heteroalkyl; R3 = alkyl, heteroalkyl, cycloalkyl, heterocyclyl, etc.; n = 0-3], were prepared for pharmaceutical use as inhibitors of p38 protein kinase for the treatment of conditions such as arthritis, Crohn's disease, obstructive pulmonary disease, or irritable bowel syndrome.. Thus, dihydropyrimido[4,5-d]pyrimidinone II (R = NHCHMe₂, R3 = CH₂CO₂H) was prepared via a substitution reaction of H₂NCHMe₂ with sulfone II (R = SO₂CH₂Ph, R3 = CH₂CO₂Et) when combined and heated to 90-100° for 1 h. The prepared dihydropyrimido[4,5-d]pyrimidinone derivs. showed p38 50% inhibitory activity at concns. < 10 μM.

IT 335318-15-5P 335318-19-9P 335318-22-4P


335318-39-3P 335318-40-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)


RN 335318-15-5 . HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-hydroxyethyl)-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 335318-19-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 335318-22-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 335318-39-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 335318-40-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-methoxyethyl)-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




IT 335318-09-7P 335318-10-0P 335318-11-1P
 335318-12-2P 335318-16-6P 335318-17-7P
 335318-18-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)


RN 335318-09-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-1(2H)-acetic acid, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 335318-10-0 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-methoxyethyl)-7-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335318-11-1 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 335318-12-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-1-(2-hydroxyethyl)-7-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 335318-16-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2R)-2,3-dihydroxypropyl]-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335318-17-7 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(2S)-2,3-dihydroxypropyl]-3,4-dihydro-7-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335318-18-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 335318-27-9P 335318-33-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkylamino substituted pyrimidino[4,5-d]pyrimidines for pharmaceutical use as inhibitors of p38 protein kinase)

RN 335318-27-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-3,4-dihydro-7-[(1-methylethyl)amino]-1-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 335318-33-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-3,4-dihydro-7-[(1-methylethyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 11 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:291041 HCPLUS

DOCUMENT NUMBER: 132:308352

TITLE: Preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors

INVENTOR(S): Harris, William; Hill, Christopher Huw; Smith, Ian Edward David

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024744	A1	20000504	WO 1999-EP7675	19991013
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2347474 AA 20000504 CA 1999-2347474 19991013
 BR 9914677 A 20010717 BR 1999-14677 19991013
 EP 1123295 A1 20010816 EP 1999-953796 19991013
 EP 1123295 B1 20040929
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 TR 200101102 T2 20020121 TR 2001-200101102 19991013
 JP 2002528455 T2 20020903 JP 2000-578314 19991013
 JP 3593035 B2 20041124
 NZ 510760 A 20030829 NZ 1999-510760 19991013
 AU 769989 B2 20040212 AU 2000-10363 19991013
 AT 277931 E 20041015 AT 1999-953796 19991013
 US 6150373 A 20001121 US 1999-422451 19991021
 ZA 2001002652 A 20020930 ZA 2001-2652 20010330
 HR 2001000274 A1 20020630 HR 2001-274 20010412
 NO 2001001929 A 20010419 NO 2001-1929 20010419
 HK 1041483 A1 20041224 HK 2002-103084 20020424
 PRIORITY APPLN. INFO.: GB 1998-23277 A 19981023
 GB 1999-20044 A 19990824
 WO 1999-EP7675 W 19991013

OTHER SOURCE(S) : MARPAT 132:308352
 GI



AB Title compds. [I; R1 = NH₂, alkylamino, (hetero)aryl(alkyl)amino; R2 = alkyl (hetero)aryl(alkyl); R3 = H, alkyl, (hetero)aryl(alkyl), cycloalkenyl] were prepared. Thus, Et 4-chloro-2-methylthiopyrimidine-5-carboxylate was aminated by MeNH₂ and the product converted to the aldehyde which was condensed with 2,6-Cl₂C₆H₃NH₂ to give 2,6-Cl₂C₆H₃NHCH₂ZNHMe (Z = 2-methylthiopyrimidine-5,4-diyl). The latter was cyclocondensed with COCl₂ and the product oxidized to give I (R2 = 2,6-Cl₂C₆H₃NHCH₂, R3 = Me) (II; R1 = SO₂Me) which was aminated by 4-(H₂N)C₆H₄OCH₂CH₂NEt₂ (preparation given) to give II [R1 = 4-(Et₂NCH₂CH₂O)C₆H₄NH]. Data for biol. activity of I were given.


IT 266312-86-1P 266312-87-2P 266312-88-3P
 266312-93-0P 266312-94-1P 266312-95-2P
 266312-97-4P 266312-98-5P 266312-99-6P
 266313-00-2P 266313-01-3P 266313-02-4P
 266313-03-5P 266313-04-6P 266313-05-7P
 266313-06-8P 266313-07-9P 266313-08-0P
 266313-09-1P 266313-10-4P 266313-11-5P
 266313-12-6P 266313-13-7P 266313-14-8P
 266313-15-9P 266313-17-1P 266313-18-2P
 266313-19-3P 266313-20-6P 266313-21-7P
 266313-22-8P 266313-23-9P 266313-24-0P
 266313-25-1P 266313-27-3P 266313-29-5P
 266313-30-8P 266313-31-9P 266313-32-0P

266313-33-1P 266313-34-2P 266313-36-4P
 266313-37-5P 266313-38-6P 266313-39-7P
 266313-40-0P 266313-41-1P 266313-42-2P
 266313-43-3P 266313-44-4P 266313-45-5P
 266313-46-6P 266313-47-7P 266313-48-8P
 266313-49-9P 266313-50-2P 266313-51-3P
 266313-52-4P 266313-53-5P 266313-54-6P
 266313-55-7P 266313-56-8P 266313-57-9P
 266313-58-0P 266313-59-1P 266313-60-4P
 266313-61-5P 266313-62-6P 266313-63-7P
 266313-64-8P 266313-65-9P 266313-66-0P
 266313-67-1P 266313-68-2P 266313-69-3P
 266313-70-6P 266313-71-7P 266313-73-9P
 266313-74-0P 266313-75-1P 266313-76-2P
 266313-77-3P 266313-78-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)


RN 266312-86-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266312-87-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266312-88-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 266312-93-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266312-94-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266312-95-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 266312-97-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-(3-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 266312-96-3


CMF C30 H31 Cl2 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 266312-98-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 266312-99-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-00-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-01-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-02-4 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(dimethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)

)




RN 266313-03-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[4-(2-hydroxyethyl)phenyl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-04-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-[(2-phenylethyl)amino] - (9CI) (CA INDEX NAME)




RN 266313-05-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[(2,4-dimethoxyphenyl)methyl]amino] -3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-06-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-07-9 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-(cyclohexylamino)-3-(2,6-

dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-08-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-09-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 266313-10-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(cyclohexylmethyl)amino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-11-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-(1-naphthalenylamino)-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-12-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[4-(aminomethyl)phenyl]methyl]amino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-13-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[[2-(4-aminophenyl)ethyl]amino]-3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-14-8 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[[4-[2-(diethylamino)ethoxy]phenyl]methyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-15-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(2,6-dimethylphenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-17-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-(1-methylethyl)-(9CI)
(CA INDEX NAME)



RN 266313-18-2 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)-(9CI) (CA INDEX NAME)



RN 266313-19-3 HCAPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-

phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-20-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(4-methoxyphenyl)methyl]amino]-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-21-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-22-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(2,6-difluorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-23-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-24-0 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,6-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl- (9CI) (CA INDEX NAME)




RN 266313-25-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-27-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-29-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-(2-cyclohexen-1-yl)-3-(2,6-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-30-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-31-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,5-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-32-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-bromophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 266313-33-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-methoxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-34-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-hydroxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-36-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-amino-3-(2-bromophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 266313-37-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-38-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,6-dimethylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-39-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-[2-chloro-4-(trifluoromethyl)phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-40-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-41-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-chloro-6-methylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-42-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,5-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-43-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 266313-44-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[3-(2-hydroxy-1,1-dimethylethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-45-5 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-1,1-dimethylethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-46-6 HCAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 266313-47-7 HCAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[(4-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 266313-48-8 HCAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-49-9 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[3-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-50-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[4-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-51-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[4-(aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-52-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-(1-naphthalenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-53-5 HCAPLUS

CN Benzoic acid, 3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-ylmethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 266313-54-6 HCAPLUS

CN Benzoic acid, 3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-ylmethyl]- (9CI) (CA INDEX NAME)




RN 266313-55-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-ethoxyphenyl)amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-56-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-57-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-[(2-methylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-58-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-59-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-60-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-61-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[(methylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)

MeNH—CH₂—CH₂


RN 266313-62-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-[(dimethylamino)ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)

Me₂N—CH₂—CH₂


RN 266313-63-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-(cyclohexylmethyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-64-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[4-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-65-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[4-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-66-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 266313-67-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-[(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 266313-68-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266313-69-3 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266313-70-6 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 266313-71-7 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-2-methylpropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-73-9 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-[1-(aminomethyl)-1-ethylpropyl]phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 266313-72-8
 CMF C₃₀ H₃₀ Cl₂ N₆ O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 266313-74-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(3-aminopropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-75-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-[2-(diethylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-76-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[(2-(4-morpholinyl)ethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266313-77-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-1-[3-[(2-(1-piperazinyl)ethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 266313-78-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(2-furanyl)methyl]amino-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




IT 266314-05-0P 266314-38-9P 266314-39-0P
 266314-40-3P 266314-45-8P 266314-46-9P
 266314-47-0P 266314-48-1P 266314-49-2P
 266314-51-6P 266314-62-9P 266314-63-0P
 266314-71-0P 266314-78-7P 266314-79-8P
 266314-83-4P 266314-84-5P 266314-86-7P
 266314-91-4P 266314-92-5P 266314-93-6P
 266315-34-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)


RN 266314-05-0 HCPLUS

CN Benzeneacetic acid, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 266314-38-9 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 266314-39-0 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,6-dimethylphenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl] - (9CI) (CA INDEX NAME)




RN 266314-40-3 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-[2-chloro-4-(trifluoromethyl)phenyl]-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl] - (9CI) (CA INDEX NAME)




RN 266314-45-8 HCAPLUS

CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-1-[3-[2-[(1,1-dimethylethyl)diphenylsilyloxy]ethyl]phenyl]-3,4-dihydro-7-(phenylamino) - (9CI) (CA INDEX NAME)




RN 266314-46-9 HCPLUS

CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-3,4-dihydro-1-[3-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266314-47-0 HCPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[(2-[(3-[(2-chloro-6-methylphenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-48-1 HCPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[(2-[(3-[(2,5-dichlorophenyl)-3,4-dihydro-2-

oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI)
 (CA INDEX NAME)




RN 266314-49-2 HCPLUS

CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-[3-[2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1,1-dimethylethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-51-6 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-bromophenyl)-1-[3-[2-[(1,1-dimethylethyl)diphenylsilyl]oxy]-1,1-dimethylethyl]phenyl]-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 266314-62-9 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[[3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 266314-63-0 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 266314-71-0 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[[4-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 266314-78-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-[3-[2-[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]phenyl]-3,4-dihydro-7-(phenylamino)-(9CI) (CA INDEX NAME)




RN 266314-79-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)-(9CI) (CA INDEX NAME)




RN 266314-83-4 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl] - (9CI) (CA INDEX NAME)




RN 266314-84-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)




RN 266314-86-7 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI)
(CA INDEX NAME)




RN 266314-91-4 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-[3-[2-[(1,1-dimethylethyl)diphenylsilyloxy]ethyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 266314-92-5 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-[2-[(methylsulfonyloxy)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 266314-93-6 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl] - (9CI) (CA INDEX NAME)



RN 266315-34-8 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[3-[3-(2,6-dichlorophenyl)-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]propyl] - (9CI) (CA INDEX NAME)



REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 12 OF 12 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:764041 HCPLUS
 DOCUMENT NUMBER: 132:22971
 TITLE: Preparation of oxopyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors
 INVENTOR(S): Dobrusin, Ellen Myra; Hamby, James Marino; Kramer, James Bernard; Schroeder, Mel Conrad; Showalter, Howard Daniel Hollis; Toogood, Peter; Trumpp-Kallmeyer, Susanne A.
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961444	A2	19991202	WO 1999-US10187	19990510
WO 9961444	A3	20000203		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2329703	AA	19991202	CA 1999-2329703	19990510
AU 9940734	A1	19991213	AU 1999-40734	19990510
AU 763839	B2	20030731		
BR 9911590	A	20010213	BR 1999-11590	19990510
EP 1080092	A2	20010307	EP 1999-924165	19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200003429	T2	20010723	TR 2000-200003429	19990510
JP 2002516327	T2	20020604	JP 2000-550849	19990510
EE 200000706	A	20020617	EE 2000-706	19990510
NZ 508268	A	20040227	NZ 1999-508268	19990510
ZA 2000006536	A	20020211	ZA 2000-6536	20001110
BG 104960	A	20011031	BG 2000-104960	20001117
HR 2000000799	A1	20010630	HR 2000-799	20001120
NO 2000005928	A	20001123	NO 2000-5928	20001123
HK 1039483	A1	20040618	HK 2001-107828	20011108
US 2004044012	A1	20040304	US 2003-638848	20030811
PRIORITY APPLN. INFO.:			US 1998-86708P	P 19980526
			US 1999-126158P	P 19990325
			WO 1999-US10187	W 19990510
			US 2000-623737	A3 20000907

OTHER SOURCE(S): MARPAT 132:22971
 GI



AB Title compds. [I; G = NR₂ or CHR₂; R = NHR₁ or SOO-2R₁; R₁,R₂ = H, (cyclo)alkyl, (un)substituted PH, -pyridyl, etc.; R₃ = groups cited for R₁, OH, alkoxy(carbonyl), etc.; R₄ = H; R₃R₄ = bond; R₈,R₉ = H, halo, NH₂, alkoxycarbonyl, etc.; X = O, S, (alkyl)imino, etc.; Z = N or CH] were prepared as cyclin-dependant and tyrosine kinase inhibitors. Thus, 5-aminomethyl-4-cyclopentylamino-2-methylthiopyrimidine (preparation given) was cyclocondensed with 1,1'-carbonyldimidazole and the oxidized product aminated by 4-(MeO)C₆H₄NH₂ to give I [G = cyclopentylimino, R = 4-(MeO)C₆H₄NH₂, R₃ = R₄ = R₈ = R₉ = H, X = O]. Data for biol. activity of I were given.


IT

251370-13-5P 251370-14-6P 251370-15-7P
 251370-16-8P 251370-17-9P 251370-18-0P
 251370-19-1P 251370-20-4P 251370-21-5P
 251370-22-6P 251370-23-7P 251370-24-8P
 251370-25-9P 251370-26-0P 251370-27-1P
 251370-28-2P 251370-29-3P 251370-30-6P
 251370-31-7P 251370-32-8P 251370-33-9P
 251370-66-8P 251370-67-9P 251370-68-0P
 251371-07-0P 251371-08-1P 251371-09-2P
 251371-10-5P 251371-11-6P 251371-12-7P
 251371-13-8P 251371-14-9P 251371-17-2P
 251371-18-3P 251371-19-4P 251371-20-7P
 251371-21-8P 251371-22-9P 251371-89-8P
 251371-90-1P 251371-91-2P 251371-92-3P
 251371-93-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation)


RN 251370-13-5 HCPLUS

CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 251370-14-6 HCPLUS

CN Piperazine, 1-(aminoacetyl)-4-[[6-(2-chloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 251370-15-7 HCAPLUS

CN Piperazine, 1-(aminoacetyl)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]-
(9CI) (CA INDEX NAME)





RN 251370-16-8 HCAPLUS


CN Piperazine, 1-(aminoacetyl)-4-[[6-(3,5-dimethoxy-2-methylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 251370-17-9 HCPLUS
 CN Piperazine, 1-(aminoacetyl)-4-[[4-[(6-(3,5-dimethoxy-2,6-dimethylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 251370-19-1 HCPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-[(2-chloro-3,5-dimethoxyphenyl)amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-20-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-21-5 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-22-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[(4-[2-(diethylamino)ethoxy]phenyl)amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-23-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-24-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-(diethylamino)butyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-25-9 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[[4-(diethylamino)butyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-26-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-27-1 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 251370-28-2 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-29-3 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-30-6 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251370-31-7 HCPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)





RN 251370-32-8 HCPLUS


CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-33-9 HCAPLUS
 CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-dichloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridylamino)- (9CI) (CA INDEX NAME)




RN 251370-67-9 HCAPLUS
 CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[{4-[2-(diethylamino)ethoxy]phenyl}amino]-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)




RN 251370-68-0 HCPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-(3,5-dimethoxyphenyl)-1-ethyl-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 251371-07-0 HCPLUS

CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 251371-08-1 HCPLUS

CN Benzamide, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 251371-09-2 HCPLUS

CN Benzamide, 3-[(6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 251371-10-5 HCAPLUS

CN Benzoic acid, 3-[(6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-11-6 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(ethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-12-7 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-7-[[4-[2-(ethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-13-8 HCAPLUS

CN Benzamide, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-14-9 HCAPLUS

CN Benzamide, 4-[(6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-17-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-1-methyl-7-[(4-(4-morpholinyl)phenyl)amino]- (9CI) (CA INDEX NAME)




RN 251371-18-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-7-[(3-(hydroxymethyl)phenyl)amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 251371-19-4 HCAPLUS

CN Benzenebutanoic acid, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-20-7 HCAPLUS

CN Benzenebutanoic acid, 4-[(6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-21-8 HCAPLUS

CN Benzaldehyde, 4-[(6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-22-9 HCAPLUS

CN Benzaldehyde, 4-[(6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 251371-89-8 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[(2-[(4-pyridinylmethyl)amino]ethyl)amino]- (9CI) (CA INDEX NAME)




RN 251371-90-1 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-91-2 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-92-3 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)




RN 251371-93-4 HCAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[3-(diethylamino)propyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



=> d que stat 127
L24 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L26 790 SEA FILE=REGISTRY SSS FUL L24
L27 12 SEA FILE=HCAPLUS ABB=ON L26

=> d his ful

FILE 'REGISTRY' ENTERED AT 15:19:43 ON 14 MAY 2005

L24 STRUCTURE 651734-33-7

L25 32 SEA SSS SAM L24

L26 790 SEA SSS FUL L24

*) see dque set for structure
790 compda in Reg.*

FILE 'HCAPLUS' ENTERED AT 15:21:02 ON 14 MAY 2005

L27 12 SEA ABB=ON L26

12 cts in CAPlus